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ABSTRACT 
 
 
Gliomas, the tumors of glial cells, account for 80% of primary malignant brain 
tumors. In 2011, there were about 18,300 new cases of maligant gliomas in the United 
States alone. Patients with glioblastoma multiforme or anaplastic astrocytoma, the two 
major types of malignant gliomas, have a median survival of 14 months or 2 to 3 years, 
respectively. Therefore novel treatments for malignant glioma are urgently needed. 
 
A novel series of tetrahydroisoquinoline derivatives with antiglioma activity has 
been undergoing drug metabolism/pharmacokinetics (DMPK)-guided lead optimization. 
EDL-291 was result from structure modification of last generation compound EDL-155. 
Its preclinical pharmacokinetics were characterized in this dissertation project. In male 
Sprague Daley (SD) rats, after 10 mg/kg intravenous injection, total body clearance (CL) 
of EDL-291 was 209 mL/min/kg (CV 23.7%), 39% lower than EDL-155 but still much 
higher than rat liver blood flow. 1.2% of dosed EDL-291 was found in urine (fe) over the 
24 hr post-dose period. EDL-291 is stable in whole blood, not accumulated in red blood 
cells, but susceptible to pulmonary microsomal metabolism. Thus, extensive lung 
metabolism is the major contributor of the high CL value. The volume of distribution of 
EDL-291 at steady state (Vdss) in SD rats was 32.5 L/kg (CV 46.6%). The ratio of the 
EDL-291 brain area under concentration curve (AUC) to plasma AUC between 20 - 180 
min after intravenous injection was 14.0. The brain/plasma AUC ratio at 10 - 180 min 
after 50mg/kg subcutaneous injection to C57BL/6J mice was 4.07. The bioavailability (F) 
of EDL-291 after 40mg/kg oral gavage in SD rats was 40.4%. Attempts to reduce 
pulmonary metabolism led to the discovery of EDL-323, which had a dramatically 
reduced clearance compared to EDL-291. However, the brain penetration of EDL-323 
was significantly lower than EDL-291. Thus, further structural modifications are required 
to achieve both reduced clearance and enhanced brain penetration. 
 
Antigloma activity of EDL compounds was discovered in phenotype screening. A 
preliminary evaluation of the effect of EDL-291 on human glioma cell apoptosis 
machinery was conducted as part of the effort to elucidate its mechanism of action. After 
EDL-291 treatment, active caspase-3 and the amount of cleaved PARP were increased in 
both U87MG and U-251 cells. In addition, the antiproliferative effect of EDL-291 was 
partially reversed by a caspase-3/7 inhibitor. However, neither the caspase-8 inhibitor nor 
caspase-9 inhibitor reversed the apoptotic effect of EDL-291. Decylubiquinone (dUb) can 
enhance caspase-3 activation as well as antiproliferative effect caused by EDL-291 
treatment. Therefore, dUb could be a candidate companion drug of EDL-291 analogs in 
treating glioma. 
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CHAPTER 1.    INTRODUCTION 
 
 
 In 2011, there were more than 248,000 new cases of primary malignant brain 
tumors around the world [1], while about 22,000 new cases were in the United States [2]. 
About 182,000 people [1], including 13,000 Americans [2], died from primary malignant 
brain tumors each year. 80% of these tumors are gliomas, while glioblastoma (World 
Health Organization [WHO] grade IV) is the most common (Figure 1-1) and also the 
most malignant glioma [3]. Under the current standard of care, glioblastoma patients only 
have a 14 month life expectancy after diagnosis [4]. For patients with anaplastic 
astrocytoma (WHO grade III), another major type of malignant glioma, the life 
expectancy is somewhat longer (2–3 years) [5]. New treatment options for malignant 
gliomas are urgently needed.  
 
 
1.1.  Gliomas: Status Quo 
 
 
1.1.1.  Epidemiology  
 
According to most recent CBTRUS (Central Brain Tumor Registry of the United 
States) report, incidence rate of primary brain tumors was 19.89 per 100,000 person–
years in the USA (2004 - 2008) [3]. According to Surveillance, Epidemiology, and End 
Results (SEER) Cancer Statistics Review, the incidence rate of primary malignant brain 
tumors is 6.5 per 100,000 person–years in the USA, which suggests that about 22,340 
new cases developed in 2011 [2]. The total number of primary malignant brain tumor 
deaths for the USA in 2011 is estimated to be 13,110 [2]. As shown in Table 1-1, both 
incidence and mortality rates of primary brain tumors in the USA are higher than the 
average world rates.  
 
Gliomas (International Classification of Diseases for Oncology, 3rd Edition 
[ICD-O-3]: 9380-9384, 9391-9460, 9480) are tumors (Figure 1-1) that arise from 
different types of glial cells [3]. As a broad category, gliomas represent 80% of primary 
malignant brain tumors in the USA. Gliomas also account for 30% of all primary brain 
tumors, which is only slightly less than meningioma (35%). However, only 2% of 
meningioma is malignant, while 97% of gliomas are malignant [3]. Incidence rate of 
gliomas is 6.04 (5.87 for malignant gliomas) per 100,000 person–years in the USA, 
which suggest about 19,000 new cases in 2011 [3].  
 
Based histology and presumed cell of origin, gliomas can be subdivided into 
glioblastoma, astrocytoma, oligodendroglioma, ependymoma, and a few more rare 
tumors [3]. When these subtypes are counted separately, glioblastoma is the second most 
common primary brain tumors, the most common primary malignant brain tumor, and 
also most common glioma subtype (53.9%) [3]. Incidence rate of glioblastoma was 3.20 
per 100,000 person-years in the USA, which suggests about 10,000 new cases in 2011.  
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Figure 1-1. Distribution of gliomas by histology subtypes 
 
Reprinted from “CBTRUS Statistical Report: Primary Brain and Central Nervous System 
Tumors Diagnosed in the United States in 2004-2008.” Source: Central Brain Tumor 
Registry of the United States (Hinsdale, IL). Available from: http://www.cbtrus.org/ 
reports/reports.html [accessed March 12, 2012]. (No permission needed.) 
 
 
 
 
Table 1-1．Primary malignant brain and CNS tumor incidence and mortality 
rates in 2008 (age-standardized, per 100,000 person-years)  
 
Gender Incidence rates  Mortality rates World USA  World USA 
Male 3.8 7.6  2.9 5.3 
Female 3.1 5.2  2.2 3.5 
Both 3.5 6.3  2.5 4.3 
 
 
Sources: Ferlay J, et al., GLOBOCAN 2008 v2.0, cancer incidence and mortality 
worldwide: IARC CancerBase No. 10 [Internet]. Lyon (France): International Agency for 
Research on Cancer, 2010. Available from: http://globocan.iarc.fr [accessed Janary 1, 
2012]. And Howlader N, et al., SEER cancer statistics review, 1975-2008 [Internet]. 
Bethesda (MD): National Cancer Institute (USA), 2011. Available from: 
http://seer.cancer.gov/csr/1975_2008/ [accessed Janary 1, 2012]. 
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When combined together, astrocytomas and glioblastoma account for 76% of gliomas 
[3].   
 
A wide variety of factors have been reported to be associated with elevated 
glioma risk [6]. According to the 2008 consensus from the epidemiologists in Brain 
Tumor Epidemiology Consortium (BTEC) [7], most well-established glioma risk factors 
include aging, ionizing radiation exposure and certain rare hereditary syndromes. The 
incidence rates of adult glioma increase with older age until age 80 [8]. Data compiled by 
CBTRUS shows the incidence rates of glioma in different age groups in the USA during 
2004 - 2008 are 2.4 (age 0 - 19), 2.7 (age 20 - 34), 4.1 (age 35 - 44), 6.7 (age 45 - 54), 
11.6 (age 55 - 64), 17.3 (age 65 - 74), 19.0 (75 - 84), 11.3 (85 + ) per 100,000 
person-years [3]. Ionizing radiation exposure is the only established environmental risk 
factor for glioma [6, 9, 10]. Multiple studies show a linear dose–response relationship 
between ionizing radiation exposure and glioma risk. A recent study indicates that for 
survivors of various childhood cancer in the USA and Canada, exposure to radiotherapy 
was associated with significantly increased risks for the development of subsequent 
glioma (odds ratio = 6.78), especially when the dose is higher than 30 Gy [11]. An earlier 
Israeli study shows that patients who received low dose X-ray therapy (1–6 Gy) in 
childhood for tinea capitis (ringworm of the scalp) also have a 2.6-fold increase of risk 
for glioma [12]. Another study shows that Japanese atomic bomb survivors have 
statistically significant increased risk of glioma (excess relative risk = 0.6 per Sv) [13]. 
Rare genetic syndromes, such as neurofibromatosis types 1 and 2 (germ-line mutations in 
tumor suppressor genes NF1 or NF2), tuberous sclerosis (germ-line mutations in tumor 
suppressor gene TSC1 or TSC2), the Li-Fraumeni syndrome (germ-line p53 mutations), 
and Turcot syndrome type 1 (biallelic germ-line mutations in DNA mismatch repair 
genes hPMS2, hMSH2, or hMLH1), are associated with gliomas [6, 7]. 
 
Other established glioma risk factors are male gender, Caucasian race, and 
epilepsy/seizures/convulsions [7]. The incidence rate of gliomas is higher in males (7.17 
per 100,000 person– years in the USA) than in females (5.08 per 100,000 person–years in 
the USA) [3]. When different races/ethnics in the USA are compared, whites have the 
highest incidence rate of gliomas (6.2 per 100,000 person–years), followed by Hispanic 
and American Indians/Alaska Natives (4.4 and 3.9 per 100,000 person–years, 
respectively),while Blacks and Asians/ Pacific Islanders have incidence rates (3.0 and 2.8 
per 100,000 person–years)─less than half of the rate of Whites [8]. This is consistent with 
the observation that Northern Europe, Australia, Canada, the United States, and New 
Zealand, have a primary malignant brain tumor incidence that is much higher than that of 
Asian countries, such as the Philippines, India and Japan [10]. Although considered as 
risk factors, epilepsy, seizures and convulsions are probably the early symptoms of 
glioma [7]. 
 
 Mutagen sensitivity and family history of gliomas are probable glioma risk factors 
[7]. Constructive gene polymorphisms in drug metabolism enzyme genes (GSTs, 
CYP2D6 and CYP2E1), DNA repair genes (ERC1, ERCC2, MGMT, and XRCC7), 
immune related genes (IL-4RA, IL-13, HLA-B*13, and HLA-B*07-Cw*07), as well as 
GLTSCR1, are also considered as possible risk factors. Together with the aforementioned  
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rare genetic syndromes, all these factors provide insights on a genetic predisposition to 
glioma. 
 
 The relationship between radiofrequency electromagnetic fields (non-ionizing 
radiation), especially cell phone usage and glioma risk, has been controversial [14]. A 
recent Interpone study suggests a 40% increase of glioma risk at the highest exposure 
levels (10th decile of recalled cumulative call time, ≥ 1640 h over 10 years), while no 
increase was found in other exposure levels [15]. 
 
 There are also some negative risk factors inversely associated with glioma 
incidence, such as high intake of calcium and antioxidants, usage of NSAIDs, history of 
allergies or asthma, high serological levels of IgE, history of varicella-zoster virus (VZV) 
infection (chickenpox), and presence of anti-VZV IgG [7, 10]. 
 
 
1.1.2.  Diagnosis  
 
 Patients with glioma can present symptoms including headaches, personality 
changes, nausea, vomiting, hemiparesis, sensory loss, visual loss, and seizures [16]. Since 
the symptoms are more related to the location of the tumor rather than the pathological 
properties, diagnosis of glioma may be delayed until the tumor progresses and invades to 
produce clinical symptoms. T1-weighted gadolinium-enhanced magnetic resonance 
imaging (MRI) is a standard tool for diagnosis patients with glioma. It is believed that 
tumor cells can still be found at 2 cm beyond the enhancing border. Magnetic resonance 
spectroscopy (MRS) is commonly used in the clinic to measure metabolic activity, thus 
providing important information for monitoring the therapeutic response and early 
detection of relapse. In addition, Positron emission tomography (PET) is also being 
applied in the clinic in diagnosing gliomas [17]. 
 
 
1.1.3.  Current treatment and difficulties 
 
1.1.3.1.  Surgery  
 
Surgery is the first modality for the treatment of malignant glioma [4]. However, 
in contrast to tumors that have metastasized to the brain, where sharp tumor borders are 
observed, borders of most glioma are ill-defined. Due to the high invasive and infiltration 
property of glioblastoma, groups of tumor cells or single tumor cells can detach from the 
primary tumor and travel a long distance to other sites of the brain. Thus it is not possible 
to achieve complete tumor recession during surgery, which may contribute to the poor 
prognosis of glioblastoma. Whether the extent of surgical resection statistically correlates 
with overall survival is still a controversy in the literature. But decompressing the brain 
by surgery temporally reduces the related clinical symptoms caused by the tumor, thus 
improving the quality of life. Tumor samples taken during surgery can be sent for 
histopathology review.  
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In 2006, Stummer et al. reported that 6 month event-free survival of patients with 
malignant brain tumors can be doubled using fluorescence-guided surgery [18]. They 
conducted a randomized, controlled multicentre phase III trial giving treatment group 
patients the non-fluorescent prodrug 5-aminolevulinic acid (ALA) by oral administration. 
This prodrug was then metabolized to fluorescent protoporphyrin IX (PpIX). PpIX 
accumulates high in tumor tissue and very low in normal tissue. Under blue light, 
neurosurgeons can visualize the tumor as “red” in color, thus optimizing tumor resection. 
Currently, ALA is not approved by the FDA for using during surgery.  
 
 In addition to classic surgery, neuroendoscopy provides a novel, minimally 
invasive approach for the diagnosis and treatment of glioblastoma [19]. Utilizing a fiber 
optic camera (endoscope), neuroendoscopy can be performed by a neurosurgeon to 
visualize the tumor and perform biopsy, resection, and the concurrent management of 
obstructive hydrocephalus associated with a tumor. The diameter of the neuroendoscope 
is less than 1 cm, the skin incisions are less than 2 cm, and the opening of the skull is less 
than 1 cm. This technique is very attractive, because it causes less damage to the brain 
during the surgery. The visualization property of neuroendoscopy can help in getting 
accurate glioma sampling for accurate pathological diagnosis. But some limitations of 
this technique still need to be solved before it can get widespread popularity.  
 
1.1.3.2.  Radiation therapy 
 
Radiation therapy is a mainstay treatment of malignant glioma in adults. 
Published data that showed significant prolongation of survival for patients receiving 
post-surgery radiotherapy (9 - 10 months) compared to surgery alone with supportive 
care (4 - 5 months) [20-22]. The current routine regimen is 6 weeks of fractionated (60 
Gy in 30 fractions) external-beam partial brain radiation starting at least 2 weeks after 
tumor resection [20]. If the radiation source is focused precisely on the tumor, radiation 
may cause more damage to tumor cells than it does to normal cells. The target volume for 
radiation is often set as a 2 cm ring of brain tissue beyond the preoperative 
contrast-enhancing rim of tumor determined by MRI or CT scan [20]. 
 
 Radiation therapy for recurrent glioblastoma is more toxic and risky than for 
newly diagnosed disease. Therefore, re-irradiation is limited to patients with focal disease 
and good performance status, and both treatment volumes and dose are reduced [16]. 
 
 Recent technical advances, such as modern treatment planning software and 
commercial onboard imaging systems, have improved focusing of radiation by mapping 
the tumors and setting up patients more accurately. Proton therapy is the most promising 
frontier in radiation delivery [16]. 
 
1.1.3.3.  Chemotherapy 
 
Historically, chemotherapy plays a less prominent role in glioma treatment. 
Currently, there are five FDA-approved antiglioma drugs: oral lomustine (CCNU), 
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intravenous carmustine (BCNU), oral temozolomide (TMZ), biodegradable polymer 
wafer impregnated with BCNU (Gliadel®), and monoclonal antibody bevacizumab [23]. 
 
 Nitrosoureas CCNU and BCNU got approved for brain tumors in the 1970s. They 
are DNA alkylating agents capable of crossing the blood-brain barrier (BBB) [23]. 
Adding them to radiotherapy provides a survival advantage of about 2 months. CCNU is 
a component of the once popular PCV (procarbazine, CCNU, and vincristine) 
combination therapy. BCNU has been the gold standard for evaluating new 
chemotherapy for more than 20 years. However, substantial hematopoietic, pulmonary, 
and renal toxicity have limited the usage of systemic nitrosoureas [21]. 
 
 Gliadel® are 1.4 cm × 1 mm polifeprosan 20 wafers containing 7.7 mg/disc of 
BCNU. Usually, up to 8 discs are implanted into the cavity after tumor mass resection. 
BCNU can be released into brain parenchyma over days or weeks, while the polymer 
matrix is degraded under the effect of interstitial water. The local BCNU concentrations 
can be 1200-fold higher than the concentrations after intravenous administration. In the 
meantime, peripheral toxicity can be largely reduced. Gliadel was first approved by the 
FDA in 1996 for treatment of recurrent glioblastoma. Then in 2003, the FDA approved it 
for initial treatment of all high-grade malignant gliomas since clinical trials showed that 
median survival of the Gliadel group was more than 2 months longer than the placebo 
group [21]. 
 
 TMZ is an imidazotetrazine derivative of alkylating agent dacarbazine (DTIC). It 
works as a prodrug: Under physiological pH, TMZ is hydrolyzed to the compound 
monomethyl triazone imidazole carboxamide (MTIC). Unlike other approved antiglioma 
drugs or the intravenous anti-melanoma agent dacarbazine, TMZ is almost 100% 
bioavailable and can cross BBB after oral dosing [20, 21]. Its mechanism of action is the 
methylation of DNA. TMZ got accelerated approval in 1999 for refractory anaplastic 
astrocytoma and then regular approval in 2005 for newly diagnosed glioblastoma [23]. It 
has become the current standard treatment for gliomas due to causing fewer side effects 
(mainly hematopoietic and some moderate gastrointestinal toxicity) and offering 
convenient oral dosing. The approved dosing regimen is 75 mg/m2 daily concomitantly 
with radiotherapy, followed by 200 mg/m2 for 5 days every 4 weeks for a total of 6 
months. The median survival benefit from adding TMZ to radiotherapy is 2.5 months 
[21]. 
 
 TMZ and nitrosoureas are both confronted by the drug resistance conferred by 
DNA repair enzymes in glioma cells, such as apurinic/apyrimidinic endonuclease (APE), 
poly-ADP-ribose-polymerase (PPAR), and especially the O6-methylguanine–DNA 
methyltransferase (MGMT) [4, 20, 21, 24]. MGMT silencing by the promoter 
methylation, which is found in less than half of glioblastoma patients, is associated with a 
better response to TMZ. Depletion of MGMT by using more intense TMZ dose is also 
believed to increase survival time. However, MGMT inhibitors have limited efficacy to 
boost the effect of TMZ and nitrosoureas. In a rat glioma model, PPAR inhibitor 
veliparib enhanced the efficacy of TMZ [25].  
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 In recent years, molecular targeted therapies for glioblastoma, which are supposed 
to be more effective and selective, have been a hot topic. The underlying rationale for 
these therapies is that some common genetic alterations occur within most glioblastomas, 
which lead to dysregulation of cellular signaling pathways (e.g., Ras/Raf/ PI3K, p53, and 
RB) and enable invasiveness, proliferation, evasion of apoptosis, avoidance of immune 
surveillance, and angiogenesis. Many different types of targeted agents have been 
investigated for malignant glioma treatment. They are EGFR inhibitors (gefitinib and 
erlotinib), EGFR McAbs (cetuximab and nimotuzumab), VEGFR inhibitors (cediranib), 
VEGF McAbs (bevacizumab and aflibercept), PDGFR inhibitors (imatinib), multiple 
targeted RTK inhibitor (vandetanib ,sunitinib, and sorafenib), Akt inhibitors (perifosine), 
PI3K inhibitors (BEZ235), Src/Abl inhibitors (dasatinib), PKC-β inhibitors (enzastaurin), 
farnesyltransferase inhibitors (tipifarnib and ionafarnib), mTOR Inhibitors (sirolimus, 
temsirolimus, and everolimus), proteasome inhibitors (bortezomib), HSP90 inhibitors 
(AT13387), hepatocyte growth factor McAbs (AMG-102), integrin inhibitors 
(cilengitide), as well as histone acetyltransferase and histone deacetylase (HDAC) 
inhibitors (vorinostat and depsipeptide) [26, 27]. Challenges for molecular targeted 
therapies include the molecular diversity and heterogeneity as well as redundant parallel 
signaling pathways in glioblastomas. Most single-agent clinical trials of first generation 
molecular targeted agents have been disappointing. Combination therapies may be 
helpful in overcoming this problem. Another important finding is that the toxicities of 
molecular targeted agents are higher than expected [28].  
 
 Despite of these frustrations, one molecular target agent, bevacizumab, made its 
way to FDA approval for treatment of recurrent glioblastomas in 2009. Glioblastoma is 
one of the most vascularized cancers. The level of angiogenesis mediator VEGF in 
glioblastomas is correlated with malignancy and aggressiveness as well as recurrence and 
poor survival. The accelerated approval for bevacizumab is based on high radiographic 
response rates and low toxicity. It can also provide symptom relieve by decreasing 
tumoral and peritumoral edema. The recommended dose is 10 mg/kg intravenously every 
2 weeks. Besides direct inhibition of tumor angiogenesis, other mechanisms of action of 
this drug include a direct antiglial effect on VEGF receptor-expressing tumor cells, 
disruption of the microvascular niches for tumor stem cells, as well as improvement of 
drug and oxygen delivery by vascular normalization [29-31]. 
 
 Irinotecan, a topoisomerase I inhibitor currently approved for metastatic 
colorectal cancer, can readily cross BBB. Irinotecan is synergistic with both 
temozolomide and bevacizumab in combination therapy studies for glioblastomas. The 
toxicities of these combinations are acceptable. The irinotecan and bevacizumab 
combination may significantly improve survival in newly diagnosed glioblastoma cases 
[32]. 
 
 Other novel chemotherapies under development include dendritic cell vaccines 
(DCVax), tumor-specific peptide vaccines (EGFRvIII peptides), immunotoxin (TP-38), 
radiolabeled antibodies, and various gene therapies [27]. 
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1.1.3.4.  Multimodal treatment 
 
For newly diagnosed glioblastoma, a multimodal treatment, including tumor 
resection, irradiation, and chemotherapy is recommended for adults whenever possible. 
For recurrent glioblastoma, reoperation may relieve symptoms, but can only prolong 
survival for 3 months, while re-irradiation is controversial [33]. Thus chemotherapy-only 
regimens using TMZ or bevacizumab are often adopted. Guidelines for the management 
of newly diagnosed glioblastoma [34] are summarized in Table 1-2.  
 
 
1.2.  Pharmacokinetics Considerations in Antiglioma Drug Discovery and 
Development 
 
 
1.2.1.  Role of pharmacokinetics in drug discovery and development  
 
 Drug discovery and development is a high-risk and high-cost process. A recent 
study shows that the total capitalized cost per approved new molecule have risen to 
around 1.3 billion (2005 US dollars) [35]. A significant part of this figure is the cost of 
failures, especially the attrition in clinical development. The clinical approval success 
rate in the United States is only 19% for drug candidates that entered clinical trials 
between 1993 and 2004 [36].  
 
 Since clinical development is the most expensive stage in the whole drug 
discovery and development process, an important strategy has been to “fail early” the 
compounds with poor “drugability” based on drug metabolism and pharmacokinetics 
(DMPK) evaluation. In 1991, poor pharmacokinetic characters were the most frequent 
cause (~ 40%) of attrition in clinical development [37]. By 2000, these type of issues are 
responsible for less than 10% of attrition after the pharmaceutical industry addressed this 
problem by improving the DMPK evaluation in the drug discovery stage [38].  
 
 
1.2.2.  A major challenge for antiglioma chemotherapy: the blood-brain barrier  
 
 For discovery and development of drugs that have a site of action in the brain, like 
antiglioma drugs, biopharmaceutic evaluation is critical since these drugs need to 
overcome an additional obstacle: the blood-brain barrier (BBB). 
 
 The brain is a well-perfused organ with the average human brain receiving 14% 
of cardiac output. The brain capillaries have a total length of about 400 miles, and total 
area of about 20 m2. The thickness of the endothelial cell is only 200 nm, less than 5% of 
the thickness of most cells, and each brain cell is less than 25 µm away from the blood 
flow [39]. However, more than 98% of small molecule drugs and almost all large 
molecular drugs are kept from entering the brain by the BBB ─ a combination of a 
proteinaceous layer (basal lamina) and three types of cells (brain capillary endothelial 
cells (BCECs) monolayer, astrocytes, and pericytes) [40]. 
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Table 1-2． Guideline for the management of newly diagnosed glioblastoma 
 
 
Source: Adapted with permission. Olson, JJ, et al., Management of newly diagnosed glioblastoma: guidelines development, value and 
application. J Neurooncol, 2009. 93(1): p. 1-23.  
Therapeutic modalities  Level I recommendations Level II recommendations Level III recommendations 
Neurosurgery N/A “Maximal safe resection” is 
recommended for newly 
diagnosed supratentorial 
malignant glioma in adults. 
Biopsy, partial resection or gross total 
resection is recommended to be 
considered in the initial management 
of malignant glioma. 
 
Radiation therapy Radiation therapy is 
recommended for the treatment 
of newly diagnosed malignant 
glioma in adults. Treatment 
schemes should include dosage 
of up to 60 Gy given in 2 Gy 
daily fractions that includes the 
enhancing area. 
 
Radiation therapy planning 
includes a 1 to 2 cm margin 
around the radiographically 
defined T1 contrast-
enhancing tumor volume or 
the T2 weighted 
abnormality on MRI. 
 
Chemotherapy  Concurrent and post-irradiation 
temozolomide is recommended 
in patients 18 to 70 years of age 
with adequate systemic health. 
BCNU-impregnated 
biodegradable polymers are 
recommended in patients for 
whom craniotomy is 
indicated. 
1) TMZ + radiation for patients (> 65 
years old) with newly diagnosed 
glioblastoma with KPS > 50;  2) For 
patients are ≥ 70 years old, with 
newly diagnosed glioblastoma, TMZ 
alone is a well-tolerated alternative to 
radiation therapy;  3) Radiation 
therapy, followed by one of the 
nitrosoureas, is recommended for 
those patients not eligible for TMZ.  
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Unlike endothelial cells, which are only connected by adhesion junctions to form 
the porous peripheral capillaries, BCECs are connected by both adhesion junctions and 
tight junctions. Tight junctions are protein complexes that consist of the intercellular cleft 
proteins occludin and claudins as well as junctional adhesion molecules (JAMs). 
Occludin and claudins are linked to cytoplasmic scaffolding proteins zonula-occludens 
(ZO)-1, ZO-2 and ZO-3, which are in turn linked to the actin/myosin cytoskeletal system 
via cingulin. Paracellular transportation is effectively prevented by tight junctions [40]. In 
addition, alternate transport pathways, e.g., fenestrations, transendothelial channels and 
pinocytotic vesicles are also lacking in BCECs [41]. 
  
 On the other hand, BCECs have a large number of mitochondria and drug 
metabolic enzymes that make them metabolically competent. The ABC (ATP-binding 
cassette) family of efflux transporters, e.g., P-glycoprotein (P-gp), breast cancer 
resistance protein (BCRP), and multidrug resistance protein-1,2,4,5 (MRP-1,2,4,5) are 
expressed on the luminal membrane of BCECs as an additional layer of protection from 
xenobiotics [40-42].  
 
 The outside of the BCEC is partially covered by discontinuously distributed 
pericytes. Also, the basal lamina covers both pericytes and BCECs as an extracellular 
matrix. The outermost layer of the BBB is formed by the astrocyte foot processes 
surrounding the basal lamina, pericytes, and BCECs. These astrocytes and pericytes help 
induce and maintain the properties of BBB [40]. 
 
 Given all these limiting factors, there are still some ways that molecules can cross 
the BBB and get into the brain [40, 43, 44]:  
 
 Hydrophilic polar small molecular nutrients, e.g., glucose, amino acids, 
nucleotides, nucleosides, monocarboxylates, organic cations, and organic anions, 
can enter the brain through carrier-mediated transport (CMT) i.e., via solute 
carriers (SLCs), at the luminal (blood) and basolateral (brain) side of BCECs.  
 Certain proteins and peptides, e.g., transferrin, melanotransferrin, lipoproteins, 
insulin, leptin, tumour necrosis factor α (TNF-α), epidermal growth factor (EGF), 
leukaemia inhibitory factor (LIF), and diphtheria toxin can be transported through 
receptor-mediated transcytosis (RMT). 
 Some protein with excess positive charge, e.g., histone, protamine, avidin, and 
cationised albumin can be transported through adsorptive-mediated transcytosis 
(AMT). 
 Oxygen and lipophilic non-polar small molecules may passively diffuse through 
the cell membranes and enter the brain. However, many small molecular drugs 
that enter the BCECs will be kicked back to the blood by the efflux transporters at 
the luminal side and/or exposed to drug metabolism inside the BCECs. 
 
 The blood-cerebrospinal fluid (CSF) barrier (BCSFB), which separates blood 
from the CSF in the choroid plexus, has a structure different from the BBB. The 
fenestrated choroid plexus capillary endothelium allows diffusion of small molecules,  
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while the barrier function is carried out by choroid epithelial cells that form tight 
junctions [40]. 
 
Malignant gliomas can secrete excess vascular endothelial growth factor (VEGF) 
and induce angiogenesis. In the tumor neovasculature, the tight junction proteins claudins 
and occludin as well as the cytoplasmic scaffolding protein ZO-1 are often either 
downregulated or lost. The number of pinocytic vesicles is increased in tumor endothelial 
cells [45]. In addition, abnormalities have been found in pericyte and basal lamina [45]. 
All these changes lead to a partially functional blood-brain barrier, or so-called 
blood-brain tumor barrier (BBTB) [46]. The peritumoral edema, endothelial hyperplasia, 
and gadolinium-contrast enhancing lesions in MRI are caused by this leaky barrier [45].  
 
 It has been posited that the BBB should not hinder glioma chemotherapy at all, 
since drugs should be able to pass at the leaky BBTB area [47]. However, the mainstream 
opinion is that even the BBTB is still a real barrier to transportation of antiglioma drugs. 
Although weakened, the tight junction is still present in BBTB, and the fenestrations are 
still rare (~ 2%) [45]. High interstitial pressure in the tumor caused by the leaky 
vasculature can slow drug extravasation, which can at least partially counterbalance the 
leaking-caused penetration increase [46]. Expression of some drug efflux trasporters, 
such as MRP1, is upregulated in the BBTB [46]. The most important point is that the 
leaky BBTB is only formed in the center of well-established tumors as a result of tumor 
neovascularization. The proliferating edge of the tumor and wide-spread tumor cells at 
the infiltrated area are still fed by established microvessels, thus being protected by 
normal BBB [46, 48-50]. 
 
 
1.2.3.  Strategies for enhancing brain penetration of antiglioma drugs 
 
 Various strategies have been developed to overcome the limitations of the 
BBB/BBTB on antiglioma drugs. 
 
1.2.3.1.  Circumventing BBB by local administration 
 
Challenges posed by BBB can be overcome directly by administering drugs to the 
brain interstitium. There are three types of approaches for local administration of 
antiglioma drugs: intraventricular/intracavitary injection, impregnated polymer 
implantation, and convention enhanced delivery (CED). 
 
 1.2.3.1.1.  Intracerebroventricular or intracavitary injection. A frequently used 
intracerebroventricular or intracavitary delivery device is the Ommaya reservoir, which is 
named after the inventor, Ayub Khan Ommaya. It consists of a mushroom-shaped 
self-sealing silicone dome placed under a flap of scalp and a connected catheter that goes 
to the ventricle or cavity through a small opening on the skull. Drug is injected into the 
dome first. Then the dome is flushed and gently pressed to force the drug through the 
catheter and into the brain. In this way, intermittent bolus injections of anticancer drugs 
can enter directly into the CSF, tumor cyst, or resection cavity. Prolonged 
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intracerebroventricular infusion can be carried out by other pump and catheter systems 
[49, 51, 52]. 
 
This type of drug delivery approach is limited by the slow rate of drug diffusion 
to brain parenchyma. With the intracerebroventricular route, the situation is even worse. 
Although CSF and interstitial fluid (ISF) can communicate freely, the CSF bulk flow 
passes through the ventricle and is absorbed into blood at the superior sagittal sinus in a 
rate much faster than the rate of drug diffusion. As a result, a remarkable portion of the 
intracerebroventricular-administrated drug exits to peripheral blood flow before entering 
the brain parenchyma [39]. Other disadvantages of this type of approach include infection 
and catheter obstruction [52]. 
 
  1.2.3.1.2.  Impregnated polymer implantation. Another type of local delivery 
approach is implantation of various drug-impregnated polymers into the tumor resection 
cavity. These polymer implants are different from each other in impregnated drugs, rate-
controlling mechanisms, degree of biodegradability, and also shapes and sizes [46]. 
 
 As mentioned in 1.1.3.3., Gliadel®, a poly(carboxypropane)-sebacic acid (PCPP-
SA, belonging to polyanhydrides)-based biodegradable polymer wafer containing 
carmustine (BCNU), has been approved for gliobalstoma treatment. Clinical trials for 
paclitaxel- and cisplatin-containing polymer implants have been conducted. In addition, 
polymers impregnated with other drugs, such as adriamycin, 5-fluorouracil, mitomycin, 
nimustin hydrochloride, and mitoxantrone have been studied in preclinical settings [46, 
52, 53]. Besides wafers, the polymer implant can also take the form of drug-loaded 
microspheres [49]. 
 
 Release of drug from the implant is driven by hydrolytic degradation of polymer, 
while the distribution is driven by a concentration gradient, i.e., the principle of diffusion. 
A very high drug concentration can be achieved at the tumor resection site where the 
polymer is planted [49, 52, 53], and that concentration can be maintained for weeks [48]. 
Although BCNU can pass the blood-brain barrier after systemic administration due to its 
high lipophilicity, when it is given as Gliadel, the dose-limiting systemic toxicities can be 
minimized [53]. 
 
 As a result of the diffusion process, the concentration of the drug decreases 
exponentially with distance in brain parenchyma surrounding the resection cavity [43]. 
The interstitial pressure adjacent to the cavity can also hinder the drug diffusion [53]. 
Thus, the drug concentration just millimeters away from the resection cavity is often too 
low to treat the glioma cells effectively [48, 50]. 
 
 Other limitations of the impregnated polymer approach include local 
neurotoxicity, poor wound healing, infections, cerebral edemas, and obstructive 
hydrocephalus [49, 53]. 
 
 1.2.3.1.3.  Convention-enhanced delivery. Convention-enhanced delivery (CED) 
is a novel approach proposed by Bobo et al. It infuses antiglioma drugs via a catheter (s) 
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within or around the tumor by hydrostatic pressure. Unlike the aforementioned 
intraventricular/intracavitary injection and impregnated polymer implantation 
approaches, the drug movement from the site of administration is driven by not only the 
principle of diffusion, i.e., the concentration gradient, but also the bulk flow of the 
infusate, i.e., the pressure gradient. Thus, a quicker and wider distribution can be 
achieved through CED. Targeted delivery of antiglioma drugs is achieved by selection of 
the catheter location. Using CED can limit systemic toxicity as well as widespread 
neurotoxicity [46, 50, 52].  
 
 Key parameters that need to be considered in CED are: infusion rate, catheter 
size, infusion volume, interstitial fluid pressure, particle characteristics, and tumor tissue 
structure. When carefully implemented, CED only causes inflammation within 50µm of 
the catheter surface and does not cause cerebral edema or measurable increases in 
intracranial pressure. CED has been used for delivery of viral vectors, paclitaxel, 
topotecan, transferrin/diphtheria toxin, IL-4 and IL-13 targeted toxins, IL-4, TP-38, and 
TGF-β [52].  
 
 In the other hand, CED is still plagued by a limited distribution area, like other 
local delivery routes. As a result, it is best used against small solid tumors. In order to kill 
infiltrative tumor cells, multiple catheters and multiple day infusions may be necessary. 
This makes CED a rather invasive approach. Some indigenous drawbacks of CED, such 
as catheter-induced tissue damage, reflux of solute adjacent to the catheter, “intrinsic” 
backflow of solute, and air bubbles, can lead to unpredictable and undesirable drug 
distribution [46, 48, 50, 52]. 
 
1.2.3.2.  BBB disruption 
 
Another class of strategy to overcome the limitation of BBB is to disrupt it 
physically or biochemically when administrating an antiglioma drug systemically.  
  
1.2.3.2.1.  Osmotic disruption. Intracarotid infusion of hyperosmotic solution, 
e.g., mannitol solution, can draw intracellular water to the vascular lumen from BCECs. 
This leads to BCECs shrinkage and subsequent opening of the tight junctions for hours. 
Thus the paracellular transportation is permitted at that time. Chemotherapy drugs are 
often dosed through intra-arterial route when this approach is used [49, 52, 53].  
 
 Animal studies show that osmotic BBB disruption can increase drug 
concentrations in the brain parenchyma by up to 90-fold [52]. Enhanced drug delivery to 
the brain by this method has also been shown in humans [50]. 
 
 However, this method causes greater disruption of the normal BBB than to the 
BBTB, which may result passage of toxic proteins and too much chemotherapy drug to 
normal brain tissue. Other adverse effects include physiological stress and increase in 
intracranial pressure [48, 50]. 
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 1.2.3.2.2.  MRI-guided ultrasound disruption. This approach can generate a focal 
BBB disruption, other than the global disruption caused by osmotic disruption [43, 52]. 
Since the cranium can attenuate ultrasound, a bone window is usually a prerequisite. 
Then the process begins with intravenous injection of preformed bubbles. The pulsed 
ultrasound guided by MRI is applied to the desired area to localize cavitation-generated 
mechanical stresses to brain capillary walls. The resulting BBB disruption is reversible 
and can completely recover in 24 hr. Increased brain penetration of herceptin and 
liposomal doxorubicin has been shown after using this approach in mice and rat, 
respectively.  
 
 1.2.3.2.3.  Biochemical disruption. Biochemical BBB disruption involves using 
vasomodulators, such as leukotrienes, histamine, bradykinin, nitric oxide donors, soluble 
guanylate cyclase activator, potassium, calcium, and ATP channel agonists. Unlike the 
osmotic disruption, this method primarily affects BBTB [48, 52]. Thus chemotherapy 
after biochemical BBB disruption is more selective on tumor mass with 
neovascularization, and is less toxic to normal brain tissue. However, as discussed in 
1.2.2, glioma cells at the edge of the tumor or infiltrated areas is still protected by normal 
BBB and thus are not exposed to drug concentration that is high enough to be effective. 
 
 Calcium can regulate tight junction assembly and the effectiveness of the tight 
junctions as a barrier [40]. Bradykinin analogue RMP-7 can indirectly activate 
calcium-mediated tight junction opening by activating B2 bradykinin receptors [43]. In 
animal studies, RMP-7 increased brain penetration of the hydrophilic compounds 
carboplatin and dextran, with greater impact in regions of BBTB [52]. However, it failed 
in clinical trials in combination with carboplatin [43].RMP-7 had no obvious impact on 
brain penetration of the lipophilic drug BCNU.  
 
 Common shortcomings of all of these three BBB disruption approaches include 
[43] requirement of anesthesia and hospitalization, potential damage of neurons caused 
by entering of some blood components, and potential of facilitating tumor dissemination. 
 
1.2.3.3.  Inhibition of drug efflux transporters 
 
Drug transporters in BBB form an additional functional barrier. Thus inhibition of 
these transporters will also benefit the drug brain penetration. P-gp is the most important 
drug efflux transporter at the BBB. Brain penetration of paclitaxel, docetaxel, and 
imatinib has been improved by co-administration of P-gp inhibitors in animal studies. 
Classical P-gp inhibitors, e.g., verapamil and cyclosporine A have low affinities and high 
toxicity. Using cyclosporine A analogue valspodar can overcome these problems. Like 
verapamil and cyclosporine A, valspodar is also a CYP3A inhibitor. This may not be a 
desirable characteristic, because CYP3A does not express at a high level in the human 
BBB [54] but plays a key role in the peripheral drug metabolisms of many drugs. The 
newest generation of P-gp inhibitors without CYP3A-inhibiting activity, such as elacridar 
(also a BCRP inhibitor), zosuquidar, and tariquidar, are better tools to increase brain 
penetration of antiglioma drugs. BCRP inbibitors such as pantoprazole may also useful 
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for this purpose [46]. Some nanocarriers , such as Pluronic block copolymers micelle can 
also inhibit drug efflux transporters in the BBB [55].  
 
1.2.3.4.  Taking advantage of BBB carriers and transporters 
 
Carrier and transporter systems in the BBB also have been utilized to develop 
noninvasive strategies for brain penetration enhancement. These strategies can be either 
using nano-sized drug carriers conjugated to ligands of those transporter systems or 
making the drug molecules mimic or directly coupled to those ligands. 
 
 OX26 is a murine monoclonal antibody (McAb) against rat transferrin receptor 
(TfR). As a peptidomimetic McAb, OX26 binds TfR through a domain not in the 
transferrin (Tf)-binding site and thus does not interfere with endogenous Tf binding. 
OX26-conjugated liposomes can significantly increase the brain penetration of 
daunomycin through TfR-mediated transcytosis [49]. 
 
 Some evidence suggests existence of a sodium-dependent, reduced glutathione 
(GSH) transporter in BBB [56]. Recently, GSH-conjugated PEGylated liposomes of 
doxorubicin showed promising results in proof-of-concept studies. 
 
 Polysorbate-80 (Tween 80)-coated nanoparticles also can increase drug brain 
uptake. The mechanism supported by most abundant evidence is as follows: The 
polysorbate-80-coated nanoparticles adsorb apolipoprotein (Apo) E or B from blood to 
their surface─in other words, indirectly conjugated to apolipoproteins─and then cross the 
BBB through low density lipoprotein (LDL) receptor-mediated transcytosis. 
Polysorbate-80 coated-poly (butylcyanoacrylate) (PBCA) nanoparticles can increase the 
brain concentration of doxorubicin after systemic administration for more than 50 times 
[57, 58].  
 
 DL-2-amino-7-bis (2-chloroethyl)amino]-l,2,3,4-tetrahydro-2-naphthoic acid 
(DL-2-NAM-7), a melphalan analog with higher affinity to large amino acid (LAT) 
transporter, shows 20 times higher brain uptake than melphalan [59]. 
 
 Angiopep-2, a 19 amino acid peptide, can cross the BBB though lipoprotein 
receptor-related protein-1 (LRP1)-mediated transcytosis. Paclitaxel conjugated to 
Angiopep-2 (ANG1005) distributes into the brain at a level 4 to 5 times higher than 
paclitaxel alone [48]. 
 
1.2.3.5.  Passive diffusion enhancement by drug structure modification 
 
The physio-chemical parameters of anticancer drugs can be tuned to optimize 
passive diffusion across the BBB. For example, making a lipophilic analog or prodrug of 
a highly hydrophilic drug may help its diffusion. More details on the optimal drug 
physio-chemical properties for brain penetration are discussed in the next section. 
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1.2.4.  Physiochemical characteristics of successful CNS drugs 
 
 Prediction of brain penetration of new chemical entities (NCEs) from their 
physiochemical properties is a hot but controversial area [60]. Following are some simple 
physiochemical rules for successful CNS drugs summarized by Pajouhesh et al. [61]: 
 
 Molecular weight < 450 
 cLogP < 5 
 H-bond donors < 3 
 H-bond acceptors < 7 
 Rotatable bonds < 8 
 Polar surface area (PSA) < 60–70 Å2 
 
 These rules can serve as a rough guideline for discovery of novel antiglioma drug 
intended for systemic administration or structure modification of current drugs. 
 
 Comparison between these rules and Linpinski’s “rule of five”, i.e., 
 
 Molecular weight ≤ 500 
 LogP ≤ 5 
 H-bond donors ≤ 5 
 H-bond acceptors ≤ 10 
 Rotatable bonds ≤ 10 
 
shows CNS drugs have lower molecular weights, less flexibility, and fewer hydrogen 
bond donors and acceptors [61]. 
 
 The limit on LogP may be explained as follows: While higher lipid solubility 
helps passing the phospholipids bilayer, it can also lower the concentration of the free 
drug available for diffusion at BBB [62] because of increased peripheral tissue and 
plasma protein binding. In addition, drugs already in the BCECs need to partition into the 
aqueous environment of brain interstitial fluid before reaching their target behind the 
BBB [41]. Also, high non-specific binding to brain tissue will hinder drugs with very 
high lipophilicity from exerting their effect. Some earlier reports even suggested a value 
around 2 as the optimal LogP for CNS drugs [61]. 
 
 Compared to the absorption process in the gastrointestinal tract, BBB crossing is 
more dependent on transcellular diffusion. The movement of lipid-soluble molecules 
through the cell membrane is hypothesized to be through transient pores created by 
kinking of the mobile unsaturated fatty acyl side chains in the phospholipid bilayer. Thus 
the size and shape of those holes determine the size and shape of the molecules that can 
pass [39]. This may explain why CNS drugs are smaller than general oral drugs and have 
more compact and less flexible structures. 
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In addition, certain physiochemical features may play a role in substrate 
specificity of efflux transporters and drug metabolism enzymes, thus affecting drug brain 
penetration. 
 
 
1.2.5.  Overview of DMPK of last generation of EDL compounds 
 
 1-[(4-phenylphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol (Figure 1-2), 
i.e. , EDL-155, also known as EDL-1, is a tetrahydroisoquinoline derivative with in vivo 
antiglioma activity selected from about 500 compounds synthesized by Dr. Duane 
Miller’s laboratory at The University of Tennessee Health Science Center (UTHSC, 
Memphis, TN) [63, 64]. It was the subject of a detailed DMPK evaluation in Pengfei 
Song’s dissertation [63]. 
 
After 10 mg/kg intravenous injection to rats, EDL-155 demonstrated 
extraordinarily rapid clearance (342.5 mL/min/kg), which is around 6 times the rat liver 
blood flow. The volume of distribution was estimated at 13.0 L/kg. Elimination of 
EDL-155 can be described by a one-compartment model [65]. EDL-155 is extensively 
bound to plasma proteins, with the percentage bound being larger than 93 at 
concentrations of 150, 650, and 2,500 ng/mL [65]. The most abundant EDL-155 
metabolite is formed by C-ring hydroxylation, which may be catalyzed by a cytochrome 
P450 enzyme. The next abundant metabolite is formed by A-ring mono-methylation, 
which may be catalyzed by catechol O-methyltransferase (COMT) in blood and tissue 
[65]. EDL-155 was predicted by Song to be a P-gp substrate using an in silico 
classification structure-activity relationship (C-SAR) model based on physicochemical 
properties, which was verified subsequently using Calcein-AM assay [63]. 
 
 Some potential reasons for the high clearance value were proposed: 1) 
accumulation in blood cells, fat, and other organs, 2) degradation/metabolism in the 
blood, 3) first pass effect in the lung, and 4) exsorption into the gut by uptake 
transporters. However, these possibilities were not examined by experiments in Song’s 
study [63]. 
 
The brain penetration of EDL-155 was evaluated in vivo by CSF sampling after 
20 mg/kg intravenous injection in rats. The dose-normalized ratio of AUCCSF/AUCPlasma 
was calculated to be 1.4% [65]. As an attempt to overcome the poor brain penetration 
problem, 9.25 mg/mL EDL-155 solution was delivered as 4 µL/min × 100 min CED 
infusion in caudate nucleus. Although EDL-155 can be detected in the contralateral 
frontal lobe, ipsilateral lobe, occipital lobe, and the cerebellum, the concentration in these 
areas is less than 0.2% of the injection site concentration [63]. 
 
 EC50 of EDL-155 is 1.5 mM for rat C6 glioma cells [64]. Despite its limited 
brain penetrability, after 7 days of 20 mg/kg intraperitoneal injections, it still can cause 
29.4% growth inhibition of the intracranial implanted C6 glioma in rats [66]. This 
suggests that analogs with increased metabolic stability and brain penetrability may 
provide a therapeutic option for glioma. 
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Molecular Weight: 331.41 
Exact Mass: 331.16 
cLogP: 4.16 
H-bond Donor: 3 
H-bond Acceptor: 3 
Rotable Bonds: 3 
PSA: 52.49 Å2 
 
 
Figure 1-2. Structure and selected physiochemical properties of EDL-155  
 
Exact mass and cLogP are calculated by ChemDraw Ultra 12.0 (CambridgeSoft 
Corporation, Cambridge, MA). All other values are calculated by Marvin Calculator 
Plugins (ChemAxon Kft., Hungary). 
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Study of analogs of EDL-155 showed that replacing the A-ring catechol hydroxyl 
groups with dimethoxy may sometimes increase metabolic stability and decrease 
clearance. However, their CSF concentration is lower than that of some EDL-155 analogs 
that keep A-ring catechol hydroxyl groups. A closer inspection showed that 
AUCCSF/AUCPlasma decreased with the increase of LogP [63]. 
 
 
1.3.  Background for Mechanism of Action Study  
 
 
1.3.1.  Drug discovery with unknown target 
 
 Phenotypic (physiological or cellular) screening is a classical drug discovery 
method [67-69]. Since 1990s, this low-through-put approach has been largely replaced by 
the molecular target-based screening, which is powered by advances in molecular 
biology, genomics, and combinatorial chemistry. However, after the initial euphoria, the 
new gene-to-drug paradigm turned out to be not as productive as expected, and was 
criticized for “targephilia” and overtly reductionism [70]. Therefore, the old route, 
phenotypic screening, has seen a renaissance, as supporters argue that it can test the 
compounds against the actual complex biological system in the very beginning [71]. In 
2002, Merck received approval of ezetimibe, a cholesterol-lowering agent discovered 
through phenotypic screening. Eli Lilly also announced a Phenotypic Drug Discovery 
(PD2) Initiative in 2009. 
 
 The phenotypic screening can bypass the prior target identification and validation, 
and thus allows discovery of drug candidates with unknown targets. However, at the 
present time, a drug candidate discovered via this route must undergo a mechanism of 
action study or even a retrospective target identification [68]. In the case of ezetimibe, if 
the decade long mechanism-finding effort had been unsuccessful, it would not likely gain 
approval. A successful mechanism study can also facilitate further optimization of 
structure, identification of potential toxicities or side effects, and selection of possible 
responders for clinical trials [67, 68, 71]. 
 
 
1.3.2.  Discovery of EDL compounds  
 
 The lead compound of EDL series compounds was found in an anti-hepatitis C 
drug discovery project at The University of Tennessee Health Science Center. It was 
designed as a blocker of CD81 (TAPA-1, target of antiproliferative antibody-1), a cell 
membrane protein that is important for Hepatitis C virus (HCV) attachment and cell 
entry. CD81 signals for antiproliferation when bound by antibodies. Rat astrocytes are 
CD81 enriched, while C6 rat glioma cells are CD81-deficient. Thus, CD81 blocker that 
mimics the effect of CD81 antibodies should have an antiproliferative effect on rat 
astrocytes but not on C6 cells. Surprisingly, that lead compound inhibits the growth of C6 
glioma cells instead of rat astrocytes [72, 73]. After that discovery, structure 
modifications were made to improve the antiglioma activity and give birth to the EDL 
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series of 1, 2, 3, 4-tetrahydroisoquinoline derivatives [64]. The cell proliferation assays of 
rat astrocytes, C6 cells, and human glioblastoma cell lines were used to screen these 
compounds. Therefore, EDL series of antiglioma compounds were discovered by 
serendipity and screened by phenotypic screening. Their mechanism of action was 
unknown before the start of this dissertation research. 
 
 
1.3.3.  Cell death pathways induced by chemotherapy 
 
 All anticancer drugs induce cancer cells’ death, but those cells die through 
different pathways. The five major modes of cell death induced by chemotherapy are 
apoptosis, autophagic cell death, necrosis, mitotic catastrophe, and senescence [74]. 
 
1.3.3.1.  Apoptosis 
 
Apoptosis also called type I programmed cell death, is a well-known means of 
cancer cell death after chemotherapy. The morphologic characters of apoptosis include 
cell shrinkage, nuclear condensation and fragmentation, exposing of phosphatidylserine 
on the cell surface, membrane blebbing, and eventually fragmentation into 
membrane -bound apoptotic bodies. The two most well-known apoptosis signaling 
pathways are the intrinsic pathway and extrinsic pathway [74-78]. 
 
 Many traditional chemotherapeutic drugs can trigger the intrinsic pathway by 
transcriptional upregulation and activation of BH3-only pro-apoptotic members of Bcl-2 
family proteins such as Bad, Bim, Bmf, Noxa, and Puma. These proteins can antagonize 
the effect of BH1-2-3-4 anti-apoptotic members of the BCL2 family proteins, such as 
Bcl-2, Bcl-xl, and Mcl-1. The changed balance between BH3 only and BH1-2-3-4 
proteins induces homooligomerization and mitochondrial outer membrane insertion of 
the BH1-2-3 pro-apoptotic members of the Bcl-2 family proteins, like Bax and Bak, then 
lead to mitochondrial outer membrane permeabilization (MOMP) through a MPT 
(mitochondrial permeability transition)-dependent or a MPT-independent mechanism. 
 
 MOMP is a critical event in the intrinsic pathway; it demarcates the boundary 
between death and survival. Once triggered, it irreversibly leads to cell death through 
three mechanisms: 1) release of proteins that help caspase activation, such as cytochrome 
C, Smac/DIABLO, and Omi/HtrA2; 2) release of pro-apoptotic proteins unrelated to 
caspase activation, such as AIF (apoptosis-inducing factor) and Endo G (endonuclease 
G); and 3) loss of mitochondrial functions essential for cell survival.  
 
 Cytochrome C released in MOMP binds Apaf-1, resulting in the formation of a 
complex called apoptosome in the presence of ATP/dATP. The apoptosome can recruit 
procaspase-9, cause procaspase-9 oligerization and auto-cleavage, which generates the 
caspase 9. The caspase-9 and the apoptosome then form an active holoenzyme to activate 
downstream executioner caspases -3, -6 and -7 through an internal cleavage to separate 
the large and small subunits. The executioner caspase activities are essential for the 
apoptotic phenotype. The bona fide substrates of executioner caspases include PARP,  
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DFF45/ICAD, Rb, and ROCK I. As a positive feedback mechanism, the executioner 
caspases also activate caspase-9.  
 
 IAPs (inhibitor of apoptosis proteins), such as XIAPs (X-linked inhibitor of 
apoptosis proteins), inhibit caspase activity by directly binding to the active enzymes. 
Smac/DIABLO and Omi/HtrA2 can enhance caspase activation as competitive inhibitors 
of IAPs. 
. 
 The so-called caspase-independent apoptosis is mediated by aforementioned AIF 
and Endo G. They can translocate to the nucleus, induce peripheral chromatin 
condensation and DNA fragmentation without the involvement of caspases. 
 
 Sometimes chemotherapeutic drugs can also activate the extrinsic apoptosis 
pathway by upregulating the plasma membrane death receptors Fas, TNFR1, or DR4/5 
through the involvement of p53. Binding of homotrimeric death ligands FasL, TNF-α, or 
TRAIL to corresponding death receptors induces oligomerization of the death receptors. 
The resultant ligand-receptor complex then further forms a DISC (death-inducing 
signaling complex) by recruiting adapter proteins, such as FADD (Fas-Associated protein 
with Death Domain) and TRADD (TNF-R1-Associated Death Domain). Three molecules 
of procaspase-8/10 can join the DISC by binding to FADD, and then are activated by 
auto-cleavage. In some cases (type I cells), the activation of executioner caspases -3, -6, 
and -7 by caspase-8 and -10 is sufficient for apoptosis. In other cases (type II cells), the 
caspase-8 also activate Bid, a pro-apoptosis member of the Bcl-2 family, thus activating 
the intrinsic pathway. 
 
 A newer class of chemotherapy drugs, i.e., apoptosis-inducing molecular targeted 
drugs, kills cancer cells by modulating the activity of particular molecules involved in 
apoptosis, which are often dysregulated or even mutated in cancer cells [74-76]. 
Examples of these drugs include TRAIL ligand, TRAIL antibody, BH3 mimic 
(gossypol), Bcl-2 antisense oligonucleotide, and proteasome inhibitor (bortezomib). 
 
 In addition to the aforementioned intrinsic, extrinsic, and caspase-independent 
pathway, an ER (endoplasmic reticulum) stress-induced apoptosis pathway has been 
reported recently [77-84]. Human caspase-4 and mice caspase-12 [85] are the initiator 
caspases in this route [86]. They can directly activate caspase-3 [85, 87] and thus trigger 
the downstream apoptosis events. Celecoxib, bortezomib and tunicamycin are examples 
of drugs that induce apoptosis through this pathway [79].  
 
1.3.3.2.  Autophagic cell death 
 
“Autopahgy” means self-eating. Briefly, in this process, a double membrane 
vesicle forms in the cytosol that encapsulates whole organelles and bulk cytoplasm. 
These so-called autophagosome structures then fuse with the lysosomes where the 
contents are degraded and recycled [74-76, 88-90]. 
 
Autophagy can be triggered by various stimuli, including chemotherapy, 
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radiation, nutrient deprivation, growth-factor withdrawal, bacterial infection, aggregated 
and misfolded proteins (ER stress), and damaged organelles [74-76, 88-90]. In many 
case, autophagy can be a pro-survival mechanism. It can produce amino acids during 
nutrient starvation and eliminate unwanted and damaged organelles and molecules, thus 
increasing the chance of a cell to survive stresses. But when this process becomes too 
extensive, it leads to autophagic cell death, or type II programmed cell death [74-76, 
88-90] . 
 
The molecular events leading to autophagy are briefly summarized as follows 
[74-76, 88-90]: Autophagy begins from cup-like double-layered membrane structures, the 
isolation membranes. This autophagy induction/membrane nucleation process is 
regulated by type I PI3K (phosphoinositide 3-kinase), type III PI3K, and mTOR 
(mammalian target of rapamycin). Type I PI3K is active in a nutrient-rich environment 
and can activate the mTOR through the serine/threonine protein kinases PDK1 
(phosphoinositide-dependent kinase-1) and Akt (PKB). mTOR is a serine/threonine 
kinase that inhibits autophagy through controlling transcription, translation, and 
modification of autophagy-related (Atg) proteins. Thus inhibition of the type I 
PI3K-mTOR pathway can induce autophagy. mTOR activity can also be affected by 
many other mechanisms, and thus can coordinate signaling pathways that are initiated by 
many nutritional and mitogenic factors. Autophagy can also be induced by lowering 
inositol trisphosphate (IP3) level, an mTOR-independent way. Vps34, a type III PI3K 
that includes berclin-1 (Atg6) in its complex, promotes the nucleation of autophagic 
vesicles. 
 
 Autophagosomes are formed after elongation and closure of the isolation 
membranes, which engulf the cytoplasmic materials (cytosol and/or organelles) [74-76, 
88-90]. Two ubiquitin-like conjugation systems are part of this process. One system 
involves the covalent conjugation of Atg12 to Atg5, with the help of the E1 
(ubiquitin-activating enzyme) -like enzyme Atg7 and the E2 (ubiquitin carrier) -like 
enzyme Atg10. Atg16L-binding to the Atg12-Atg5 complex is necessary for the 
elongation of the isolation membrane and formation of the autophagosomal membrane. 
This complex finally dissociates from the mature autophagosome. The second system 
involves the conjugation of phosphatidylethanolamine (PE) to microtubule-associated 
protein 1-light chain 3 (LC3)/Atg8 by the sequential action of the protease Atg4, the 
E1-like enzyme Atg7, and the E2-like enzyme Atg3. Lipid conjugation causes conversion 
of the soluble form of LC3 (named LC3-I) to the autophagic vesicle-associated form 
(LC3-II).The targeting of LC3-PE to the isolation membrane or autophagosomal 
membrane relies on the Atg12-Atg5 complex, but it will keep binding to the membrane 
after Atg12-Atg5 leaves.  
 
 As the last step, the autophagosomes fuse with lysosomes [74-76, 88-90]. Before 
this fusion, the autopahgosomes can fuse with endosomal vesicles first (amphisome). The 
autophagosome outer membrane fuses with the lysosome (or endosome) membrane while 
the inner sac (autophagic body) enters the lysosome, where its membrane as well as the 
luminal content is degraded by lysosomal enzymes that act optimally within this acidic 
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compartment. The formed single membrane-surrounded vesicle is called an 
autophagolysosome or autolysosome.  
 
 The current first-line antiglioma drug, DNA-alkylating agent TMZ can induce 
both autophagic cell death and apoptosis. Other drugs or drug candidates that can induce 
autophagy in cancer cells include mTOR inhibitors everolimus and deforolimus, arsenic 
trioxide, ceramide, endostatin, the histone deacetylase (HDAC) inhibitors butyrate and 
vorinostat, neodymium oxide, saponins, curcumin, and resveratrol [74-76, 88-90].  
 
1.3.3.3.  Necrosis 
 
Necrosis can be defined morphologically as cell and organelle swelling, or rupture 
of surface membranes with spillage of intracellular contents [74, 75, 91]. Necrosis was 
thought to be an uncontrolled process. But recently, more and more evidence shows that 
necrosis can be a regulated event [74, 75, 91]. Some researchers called the regulated form 
of necrosis type III programmed cell death. Inducers of necrosis include DNA damage, 
inhibition of cellular energy production (ATP depletion), imbalance of intracellular 
calcium flux, viral infection, excess generation of reactive oxygen species (ROS), and 
activation of nonapoptotic proteases (e.g., calpain and cathepsin).  
 
 Necrosis can also be induced by chemotherapy [74, 75, 91]. DNA-alkylating 
agents can activate PARP, while the hyperactivation of PARP depletes cytosolic 
nicotinamide adenine dinucleotide (NAD) and induces necrosis. Photodynamic treatment, 
β-lapachone, apoptolidin, and honokiol can also induce necrosis in cancer cells. Necrosis 
inducing is not likely to be a promising approach to treat gliomas. In fact, 
pseudopalisading necrosis is a hallmark of glioblastoma. 
 
1.3.3.4.  Mitotic catastrophe 
 
Mitotic catastrophe refers to death that occurs during mitosis, resulting from a 
combination of deficient cell-cycle checkpoints and cellular damage [75, 92, 93]. The 
aforementioned cell-cycle checkpoints can be DNA structure checkpoints or the spindle 
assembly checkpoint. Since cancer cells often have deficient cell cycle checkpoints, when 
compared to normal cells, cancer cells are more susceptible to the induction of mitotic 
catastrophe by chemotherapy drugs acting as DNA damaging agents or microtubule 
poisons. 
 
 Some researchers believe that mitotic catastrophe is not an independent mode of 
cell death [75, 92, 93]. They propose an alternative definition: Mitotic catastrophe is a 
process characterized by the formation of multinucleated cells resulting from aberrant 
mitosis, and is a “prestage” of apoptosis or necrosis.  
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1.3.3.5.  Senescence 
 
Senescence is a state of permanent cell-cycle arrest [92, 94]. Senescent cancer 
cells although alive, can be cleared by immune cells, resulting in cancer regression. 
Therefore, senescence is also included in the cell death pathways.  
 
 Cellular stresses can activate tumor suppressors, e.g., p53, INK4A and ARF, and 
trigger senescence [92, 94]. Senescent cells can secrete both tumor-suppressing factors 
that reinforce the senescent phenotype and tumor-promoting factors that stimulate 
malignant phenotypes in nearby cells. In pre-malignant tumors, most cells are senescent. 
In malignant tumors, their ability to undergo senescence is impaired, but they can still be 
forced into senescence by chemotherapy [92, 94]. In vitro studies show that classic 
chemotherapy often induces senescence at moderate doses and apoptosis at higher ones. 
Senescence markers have also been found in biopsy from patients undergoing 
chemotherapy.  
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CHAPTER 2.    PHARMACOKINETICS OF EDL-291 
 
 
2.1.  Introduction 
 
As described in 1.2.5, previous studies show that replacement of the A-rings 
catechol group in EDL-155 with dimethoxy may decrease the clearance (CL) by blocking 
the metabolic “soft-spot”. However, the increase of LogP caused by this modification 
may also decrease the brain penetration [63].  
 
Based on these findings, efforts were made by our collaborating laboratories to 
decrease the LogP, block the metabolic “soft-spot,” and increase antiglioma potency at 
the same time. EDL-291, i.e., 6,7-dimethoxy-1-[4- (4-methoxypyridin-3-yl) phenyl] 
methyl-1,2,3,4-tetrahydroisoquinoline, is one of the best EDL-155 analogs to achieve 
these goals. Chemical structure and selected physiochemical properties of EDL-291 are 
shown in Figure 2-1. By also replacing the C phenyl ring with 4-methoxypyridin while 
blocking the A-rings catechol group, the LogP is reduced rather than increased. A pilot 
study indicates that at 10 min after intravenous (though vena cava) injection of 10 mg/kg 
to rats, the brain concentration of EDL-291 is higher than that of EDL-155 (2.45 vs. 1.16 
ng/mg). In addition, the EC50 on C6 rat glioma cells is also reduced from 1.5 to 0.6 mM 
[95]. Therefore, EDL-291 could be a promising drug candidate for glioma treatment. And 
this warrants a detailed, preclinical pharmacokinetic characterization.  
 
 
2.2.  Materials and Methods 
 
 
2.2.1.  Materials 
 
Ammonium acetate (ACS), HPLC grade acetonitrile and HPLC grade water were 
purchased from Fisher Scientific (Fair Lawn, NJ). Heparinized drug free rat plasma (Cat# 
ES1009P, Lot# 341234-P) was obtained from Biomeda (Foster City, CA). Test 
compounds EDL-115 (internal standard for EDL-155), EDL-155, EDL-291 (internal 
standard for EDL-313 and EDL-291MD), EDL-291MD, EDL-313 (internal standard for 
EDL-291) and EDL-323 were synthesized in Dr. Duane Miller’s laboratory. 
 
 
2.2.2.  LC/MS/MS method 
 
The LC/MS/MS system was composed of an AB Sciex (Foster City, CA) API 
3000 tandem mass spectrometer and Shimadzu (Columbia, MD) LC-10ADvp pumps, and 
a LEAP (Carrboro, NC) HTS PAL autosampler. Data were processed using Analyst® 
software 1.4.2 (AB Sciex, Foster City, CA).  
 
Chromatographic separation was performed using a Cadenza CD-C18 column 
(100 × 2.0mm, 3 μm, purchased from Silvertone Sciences, Philadelphia, PA). Mobile  
 26 
NH
N
O
CH3
O
CH3
O
CH3
 
 
Molecular Weight: 390.47 
Exact Mass: 390.19 
cLogP: 4.16 
H-bond Donor: 1 
H-bond Acceptor: 5 
Rotable Bonds: 6 
PSA: 52.61 Å2 
 
  
Figure 2-1. Structure and selected physiochemical properties of EDL-291 
 
Exact mass and cLogP are calculated by ChemDraw Ultra 12.0 (CambridgeSoft 
Corporation, Cambridge, MA). All other values are calculated by Marvin Calculator 
Plugins (ChemAxon Kft., Hungary). 
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phase, consisting of A (10mM NH4Ac in HPLC grade water, pH7.4) and B (acetonitrile), 
was delivered at 0.5 mL/min. The total run time was 3.5 min. Gradient elution began at 
30% B and was held for 1 min, then increased to 70% B over 1 min, decreased to 30% B 
over 1 minute, and finished at 30% B for 0.5 min. 
 
The mass spectrometer was operated in the positive electrospray ionization (ESI) 
mode (TurboIonSpray) with the following parameters: ionspray voltage (IS) 1500 V, 
nebulizing gas (NEB) 14.0, curtain gas (CUR) 14.0, source temperature (TEM) 550.0 °C, 
collision-activated dissociation (CAD) gas 7.0, declustering potential (DP) 76.0 V, 
focusing potential (FP) 150.0 V, entrance potential (EP) 10.0 V, collision energy 31.0 V, 
collision cell exit potential (CXP) 18.00 V, deflector (DF) –200 V, channel electron 
multiplier (CEM) 2200 V, and turbo gas (GS2) 7.0 L/min.  
 
The MS/MS measurements were performed in multiple reaction monitoring 
(MRM) mode. The molecule ions [M + H] + selected in Q1 were subjected to 
collision-activated dissociation by N2 in the collision cell (Q2), and the product ions were 
monitored by scanning the third quadrupole (Q3). Monitored MRM transition were 
332.4167.2 for EDL-155, 361.0 168.1 for EDL-115, 391.2→200.1 for EDL-291, 
375.0200.1 for EDL-291MD, 395.0→202.2 for EDL-313, and 379.2→202.2 for 
EDL-323. 
 
For metabolite identification, a slow gradient and Q1 scan were used. Then the 
total ion current (TIC) chromatograph was extracted using the molecular weight of each 
putative metabolite ± 0.5 amu. The possible metabolites found were further verified by 
neutral loss, precursor, and/or MRM scan. 
 
 
2.2.3.  Animals  
 
Male Sprague-Dawley rats weighing between 250 and 275 grams were purchased 
from Charles River Laboratories (Wilmington, MA) and maintained in the animal facility 
at UTHSC. Rats were fed ad libitum on normal laboratory diet and water. A 12 hr 
light-dark cycle and ambient temperature of 25 °C were maintained. Rats for the 
peripheral pharmacokinetic study were individually housed in the metabolism cages and 
rats for the CNS pharmacokinetic study were individually housed in regular plastic cages.  
 
Rats bearing both jugular and femoral vein catheters were used for the peripheral 
pharmacokinetic study after intravenous bolus injection (n = 6). Rats bearing only jugular 
vein catheters were used for the CNS pharmacokinetic study after intravenous bolus 
injection (n = 9) or for the peripheral pharmacokinetic study after oral gavage (n = 5). 
The patency of the jugular vein and femoral vein catheters was maintained every other 
day with heparinized glycerol solution (500 IU heparin/mL final solution in 75% 
glycerol) according to vendor’s instructions. 
 
Male C57BL/6J mice weighing between 25 and 35 grams were purchased from 
The Jackson Laboratory (Bar Harbor, ME) and maintained in the animal facility at 
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UTHSC. Mice were fed ad libitum on normal laboratory diet and water. A 12 hr 
light-dark cycle and ambient temperature of 25 °C were maintained. 
 
 
2.2.4.  Drug solution  
 
EDL-291 was dissolved in sterile normal saline at 10 mg/mL concentration.  
 
 
2.2.5.  Plasma protein binding 
 
Pooled rat plasma or pooled human plasma from healthy donors was spiked with 
aqueous EDL-291 stock solution to the desired concentrations (5μg/mL and 10μg/mL). 
All samples were incubated at 37 °C for 1 h before being centrifuged in Microcon 
Ultracel YM-30 (molecular weight cut-off 30,000 Da; Millipore, Billerica, MA) at room 
temperature, 10,000 g, for 15 min. Filtrate or non-filtrated spiked plasma was mixed with 
4 volume of ice-cold acetonitrile and then centrifuged at 4 °C, 10,000 g, for 5 min. 10 µL 
supernatant from each sample was injected into LC/MS/MS, respectively. Phosphate 
buffered saline (PBS) was also treated in the same way to determine the effect of 
non-specific binding. The plasma protein binding (PPB) was calculated as follows:  
 
PPB (%) = [(1 - Iu / It ) - (1 - Icu / Ict )] × 100% 
 
where Iu, It, Icu, and Ict refer to EDL-291 peak area in filtrate of spiked plasma sample, 
non-filtrated spiked plasma sample, filtrate of spiked PBS sample, and non-filtrated 
spiked PBS sample, respectively. 
 
 
2.2.6.  Erythrocyte partitioning 
 
The method used was adopted from the depletion method reported by Yu et al. 
[96]. Fresh human blood from healthy male donors was spiked to 500 nM EDL-291 
concentration. Fresh human plasma prepared from the same batch of fresh whole blood 
was used as a reference and treated in the same way. The reference plasma volume was 
identical to the whole blood volume. Both sample tubes were gently mixed and then 
incubated at 37 °C for up to 2 h. During the incubation, at 0, 60, and 120 min, a 200 μL 
aliquot of incubated whole blood was removed from each sample tubes and centrifuged 
in Microtainer® tubes with lithium heparin and plasma separation gel (Catalog # 365958, 
BD, Franklin Lakes, NJ) at 10,000 g, 4 °C for 2 min. A 50 μL aliquot of generated 
plasma was transferred into a new tube. At each of these time points, a 50 μL aliquot of 
incubated reference plasma sample was also sampled and transferred into a new tube. 200 
µL of ice-cold acetonitrile was then added to each of 50 μL plasma or whole blood 
samples. The resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10 
min. 10 µL of the supernatant was injected for LC/MS/MS analysis. The red blood cells 
partition coefficient of a given compound, KRBC/PL, is the ratio of the concentration of that 
 29 
compound in the red blood cells to concentration of that compound in plasma. KRBC/PL, 
can be determined from following equation: 
 
KRBC/PL= 
1
H
?IPL
REF
IPL
-1?+1 
 
where H = hematocrit value, IPLREF= peak area of EDL-291 in reference plasma, and  
IPL = peak area of EDL-291in equilibrating plasma from whole blood. 
 
 
2.2.7.  Stability in whole blood 
 
Fresh blood from a male SD rat was spiked to 1μM EDL-291 or EDL-155 
concentration and then incubated in a shaker at 37 °C, 250 rpm for up to 3 h. During the 
incubation, a 30 μL aliquot was removed at 0, 60, 120, and 180 min, respectively. 270 µL 
of distilled water was added first; then the mixture was vortexed for 30 s, kept at room 
temperature for 15 min, and then 1200 µL ice-cold acetonitrile with 0.1% formic acid 
(v/v) was added to the aliquot and kept at 4 °C for 15 min. The resulting mixture was 
vortexed for 30 s and then centrifuged at 10,000 g, 4 °C for 10 min. A 100 µL of the 
supernatant was mixed with 100 µL of distilled water in a glass vial, and then was kept 
at -20 °C until analysis next day. Then 10 µL was injected for LC/MS/MS analysis. The 
parent compound remaining in the incubation mixture at various time points was 
determined by comparing peak area of those time points to that of 0 min sample. 
 
 
2.2.8.  Stability to pulmonary metabolism 
 
A 4 × NADPH regenerating system master mix was prepared by mixing BD 
Gentest NADPH-regenerating system solution A (20 × ) (Catalog Number: 451220), 
solution B (100 × ) (Catalog Number: 451200), and an appropriate volume of 
HPLC-grade water. Test compound stock solution was prepared at 1 mg/mL in HPLC 
grade water. Male SD rat pulmonary microsomes (10 mg/mL) were purchased from 
XenoTech (Lenexa, Kansas). The final concentration of each component in the 
incubation system was 50 μM drug, 2.0 mg/mL microsomes, 1.3 mM NADP+, 3.3 mM 
glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, 3.3 mM magnesium 
chloride, and 50 mM pH 7.4 potassium phosphate buffer. The total volume of each 
reaction was 500 µL. The reaction was initiated by adding microsomes and was 
incubated in a 37 °C CO2 incubator. 100 µL mixtures were removed from one of the 
reactions at 0 and 120 min after start and then mixed thoroughly with 100 µL ice-cold 
acetonitrile containing IS. These samples were centrifuged at 10,000 g for 30 min, and 
the supernatant was injected into LC/MS/MS directly. 
 
The parent compound remaining in the incubation mixture at various time points 
was determined by comparing the internal standard normalized peak area of the parent 
compound (Icompound/IIS) to that of 0 min sample as follows: 
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 Percent of remaining (%) = (Icompound/IIS) t / (Icompound/IIS) 0 × 100%  
 
where (Icompound/IIS )t  and (Icompound/IIS )0 represent the internal standard normalized peak 
areas of the parent compound measured at various time points and 0 min, respectively.  
 
 
2.2.9.  Pharmacokinetic sampling and processing  
 
2.2.9.1.  Peripheral pharmacokinetics 
 
2.2.9.1.1.  Intravenous bolus injection. EDL-291 was administered (10 mg/kg) to 
SD rats (n = 6) by intravenous bolus via the femoral vein catheter. Blood (100 µL) was 
collected into Microtainer® tubes with lithium heparin and plasma separation gel from the 
jugular vein catheter at 5, 15, 30, 45, 60, 75, 90, 120, 180, 240, 360, 480, 600, and 1440 
min after dosing. Samples were centrifuged at 10,000 g, 4 °C for 2 min. Plasma was 
stored at -80 °C until analysis. Drug-free urine and feces were collected the day before 
the drug administration. At 24 hr post-dose, the feces were carefully collected into 50 mL 
polypropylene centrifuge tubes and weighed. The volume of the total urine sample was 
obtained by subtracting the bottle weight from the total weight. All the feces and urine 
samples were then stored at -80 °C until analysis using LC/MS/MS. 
 
2.2.9.1.2.  Oral gavage. EDL-291 was administered (40 mg/kg) to SD rats (n = 5) 
by oral gavage with an18G stainless steel feeding needle. Blood (100 µL) was collected 
into Microtainer® tubes with lithium heparin and plasma separation gel from the jugular 
vein catheter at 20, 40, 60, 80, 100, 120, 180, 240, 360, 480, 600, and 1440 min after 
dosing. Samples were centrifuged at 10,000 g, 4 °C for 2 min, and the plasma was stored 
at -80 °C until analysis.  
 
2.2.9.2.  CNS pharmacokinetics 
 
2.2.9.2.1.  Rat intravenous bolus injection. EDL-291 was administrated (10 
mg/kg) to SD rats (n = 9) by intravenous bolus via the jugular vein catheter. Rat was then 
anesthetized by 0.65 ml/kg ketamine/xylazine premix and perfused transcardially by 
normal saline for 2 min. Rat brains were collected at 20 min (n = 5), 90 min (n = 2), and 
180 min (n = 2) post-dose, respectively after perfusion. These samples were kept at 
-80 oC until analyzed by LC/MS/MS. 
 
2.2.9.2.2.  Mouse subcutaneous injection. EDL-291 was administered (50 mg/kg) 
to C57BL/6J mice (n = 12) by subcutaneous injection. Two of these mice were 
anesthetized by ketamine/xylazine at 5, 15, 25, 55, 85, or 175 min post-dose, 
respectively. The blood samples were collected by cardiac puncture at 10, 20, 30, 60, 90, 
and 180 min post-dose then centrifuged at 10,000 g, 4 °C for 2 min, and the plasma was 
stored at -80 °C until analysis. The brains were collected after 5 min of transcardial 
perfusion and kept at -80 oC until analyzed by LC/MS/MS. 
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2.2.9.3.  Sample preparations 
 
2.2.9.3.1.  Plasma sample preparations. 200 µL of ice-cold acetonitrile and 20 µL 
of IS (internal standard solution) were added to each of 50 μL plasma samples. The 
resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the 
supernatant was injected for LC/MS/MS analysis. 
 
2.2.9.3.2.  Feces sample preparations. 4 ml per gram of acetonitrile was added to 
feces; then the mixture was homogenized by PowerGen 125 handheld homogenizer 
(Fisher Scientific, Fair Lawn, NJ) for 30 s at maximal speed. 250 µL homogenate was 
transferred to another 2 mL tube and 20 µL of IS was added. The resulting mixture was 
vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the supernatant was 
injected for LC/MS/MS analysis. 
 
2.2.9.3.3.  Urine sample preparations. 200 µL of ice-cold acetonitrile and 20 µL 
of IS (internal standard solution) were added to each of 50 μL urine samples. The 
resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the 
supernatant was injected for LC/MS/MS analysis. 
 
2.2.9.3.4.  Brain sample preparations. 1 mL per gram of HPLC grade water was 
added to the collected brains; then the mixture was homogenized by PowerGen 125 
handheld homogenizer for 30 s at maximal speed. 100 µL homogenate was transferred to 
another 2 mL tube; then 50 µL of IS and 500 µL of ice-cold acetonitrile were added. The 
resulting mixture was vortexed and centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the 
supernatant was injected for LC/MS/MS analysis. 
 
 
2.2.10.  Pharmacokinetics data analysis  
 
The in vivo pharmacokinetic data of EDL-291 were processed using WinNonlin™ 
Professional version 5.2 (Pharsight Corporation, Mountain View, CA) for the estimates 
of pharmacokinetic parameters based on noncompartmental analysis (NCA), or 
user-defined three-compartment model (Figure 2-2). WinNonlin codes for the 
user-defined model are shown in Figure 2-3. 
 
The user defined three-compartment model was used to fit simultaneously the 
naïve averaged EDL-291 plasma concentration data from the intravenous bolus injection 
peripheral pharmacokinetics study mentioned in 2.2.9.1.1 and naïve pooled and averaged 
brain concentration data from the CNS pharmacokinetics study mentioned in 2.2.9.2.1. A 
two-compartment model analysis (without the brain compartment) was performed first to 
get the initial estimate of parameters. This approach is similar to the one used by Rai et 
al. [97]. Nelder-Mead method with iterative reweighting (1/Ŷ2) was used in minimization 
process. 
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Figure 2-2. Three-compartment user-defined model for simultaneous fitting of 
plasma and brain concentration of EDL-291 after intravenous bolus injection 
 
Boxes represent compartments. Arrows represent direction of mass transfer. The rate 
constants (k10, k12, k21, k13, and k31) are shown beside the corresponding mass transfer 
arrows. 
 
 
  
 33 
MODEL 
remark   ****************************************************** 
remark   Developer: Fei Ma 
remark     
remark   Model Version: 1.0 
remark   ****************************************************** 
remark   Brain/Plasma Conc, Clear from central compt 
remark - define model-specific commands  
COMMANDS  
NFUNCTIONS 2 
NCONSTANTS 1 
NDERIVATIVES 3 
NPARAMETERS 6 
PNAMES 'k10', 'k12','k13','k21','k31','V1' 
END 
remark - define temporary variables 
TEMP 
Dose = CON(1) 
END 
remark - define differential equations starting values 
START  
Z(1) = Dose/V1 
Z(2) = 0 
Z(3) = 0 
END 
remark - define differential equations 
DIFFERENTIAL  
DZ(1) = k21*Z(2)+k31*Z(3)-(k10+k12+k13)*Z(1) 
DZ(2) = k12*Z(1)-k21*Z(2) 
DZ(3) = k13*Z(1)-k31*Z(3) 
END 
remark - define algebraic functions 
FUNCTION 1 
F= Z(1) 
END 
FUNCTION 2 
F= Z(3) 
END 
remark - define any secondary parameters 
remark - end of model 
EOM 
 
 
Figure 2-3. WinNonlin codes for the three-compartment user-defined model in 
Figure 2-2 
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2.3.  Results 
 
 
2.3.1.  Plasma protein binding  
 
EDL-291 was extensively bound to plasma proteins with percent bound values of 
60.0, 54.4, 56.4, and 58.9 at concentrations of 5 μg/mL in rat plasma, 10 μg/mL in rat 
plasma, 5 μg/mL in human plasma, and 10 μg/mL in human plasma, respectively.  
 
 
2.3.2.  Erythrocyte partitioning 
 
In order to understand erythrocyte accumulation of EDL-291 and EDL-155, 
partition coefficient KRBC/PL was estimated for both compounds. The calculated KRBC/PL 
of EDL-291 after 0, 60, and 120 min incubation are 0.2, 0.9, and 0.6, respectively. In 
contrast, the KRBC/PL values of EDL-155 at same time points are 5.6, 8.6, and 1.4, 
respectively (Figure 2-4). Therefore, EDL-291 does not accumulate in erythrocytes at the 
tested concentration, while EDL-155 does. 
 
 
2.3.3.  Stability in whole blood 
 
As shown in Figure 2-5, EDL-291 is stable in whole blood at the concentrations 
tested, while the last generation compound EDL-155 is not. 
 
 
2.3.4.  Pulmonary metabolic stability 
 
As shown in Table 2-1, EDL-291 is susceptive to pulmonary microsomal 
metabolism. The pulmonary stability can be improved by modification of methoxy 
groups in the A-ring and C-ring. 
 
 
2.3.5.  Peripheral pharmacokinetics 
 
2.3.5.1.  Intravenous bolus injection 
 
The plasma concentration versus time profile of EDL-291 (Figure 2-6) during the 
sampling period demonstrates rapid elimination. The clearance (CL), volume of 
distribution at steady state (Vdss), terminal half-life (t1/2), and area under the curve 
(AUCiv, 0-∞) were estimated by NCA Model 201 with Linear Up/Log Down setting in 
WinNonlin 5.2. The number of data points used for estimating terminal slope λz was 
determined by Best Fit method in WinNonlin. The estimated individual pharmacokinetic 
parameters were then summarized by built-in descriptive statistics tool in the same 
software (Table 2-2). 1.2% of the dosed EDL-291 was found in urine over 24 hr 
post-dose period. The identified metabolites in plasma and feces as well as the putative 
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Figure 2-4. Erythrocyte partitioning of EDL-291 and EDL-155 
 
Concentrations of EDL-291 and EDL-155 are both 500 nM. Red blood cells partition 
coefficient KRBC/PL is the ratio of the concentration of a compound in the red blood cells 
to concentration of that compound in plasma. 
 
 
 
 
 
 
 
Figure 2-5. Stability of EDL-291 and EDL-155 in whole rat blood 
 
1μM EDL-291 or EDL-155 was spiked into fresh blood from a male SD rat and then 
incubated in a shaker at 37 °C, 250rpm for up to 3 h.  
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Table 2-1. Percentage of parent compounds remaining after 2 hr incubation with 
rat pulmonary microsomes 
 
ID Structure Percentage of parent compounds remaining 
   
EDL-155 
NH
OH
OH
100 
EDL-291 
NH
N
O
O
O
CH3
CH3
CH3
3 
EDL- 291MD 
NH
N
O
O
O
CH3
27 
EDL-313 
NH
N
Cl
O
O
CH3
CH3
53 
EDL-323 
NH
N
O
O
Cl
67 
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Figure 2-6. Plasma concentration-time profile in SD rats after 10 mg/kg intravenous bolus injection or 40 mg/kg oral gavage 
of EDL-291 
 
Intravenous bolus (IV) injection: n = 5 at 5 min, 360 min, and 1440 min; n = 1 at 600 min; n = 6 at all other time points. Oral gavage 
(PO): n = 4 at 80 min and 120 min; n = 5 at at all other time points. The error bars are standard deviations. 
PO 
IV 
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Table 2-2. Pharmacokinetic parameters of EDL-291 in male SD rats after 
intravenous bolus injection 
 
Subject CL (mL/min/kg) 
Vdss 
(L/kg) 
Terminal t1/2
(min) 
AUCiv, 0-∞ 
(min·mg/L) 
No. 2 190 28.6 465 52.6 
No. 3 252 49.4 322 39.7 
No. 4 294 60.7 338 34.0 
No. 5 167 26.3 352 59.8 
No. 6 215 36.4 492 46.5 
No. 7 166 14.4 92.0 60.3 
Geometric Mean 209 32.5 305 47.8 
CV (%) 23.7 46.6 41.3 21.9 
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pathways are shown in Figure 2-7. 
 
2.3.5.2.  Oral gavage 
The plasma concentration-time profile after oral gavage is also shown in Figure 
2-6. Oral clearance (CLoral), oral volume of distribution during terminal phase (Vdz, oral), 
terminal half-life (t1/2,z), area under the curve (AUCpo, 0-∞), maximum plasma 
concentration (Cmax), and time to reach maximum plasma concentration (tmax) were 
estimated by NCA Model 200 with Linear Up/Log Down setting in WinNonlin 5.2. The 
number of data points used for estimating terminal slope λz was determined by Best Fit 
method in WinNonlin. The estimated individual parameters were then summarized by 
built-in descriptive statistics tool in the same software (Table 2-3). The absolute 
bioavailability was calculated as ratio of dosed normalized geometric mean of AUCpo, 0-∞
and AUCiv, 0-∞. 
 
2.3.6.  CNS pharmacokinetics 
 
2.3.6.1.  Rat intravenous bolus injection 
 
The rat brain and plasma concentration profile was shown in Figure 2-8. The 
AUCbrain20 -180 min was estimated at 361 min•mg/L by noncompartmental analysis of the 
naïve pooled sparse sampling brain concentration data using WinNonlin 5.2 NCA Model 
201 with Linear Interpolation setting. By using the plasma concentration data generated 
in peripheral pharmacokinetics experiment after intravenous bolus, AUCplasma20 - 180 min , 
the geometric mean of individual plasma EDL-291 exposure during the same time, was 
estimated at 23.7 min•mg/L. Thus the rat brain to plasma AUC ratio was estimated at 
14.0. 
 
The averaged brain and plasma concentrations were also simultaneously fitted 
(Figure 2-9) into the three-compartment model shown in Figure 2-2. The final estimates 
of parameters for the model parameters are k10 = 0.164 ± 0.0246 min-1 (estimate ± 
standard error), k12 = 0.0265 ± 0.00606 min-1, k13 = 0.736± 0.419 min-1, k21= 0.00199 ± 
0.000320 min-1, k31 = 0.0817 ± 0.0404 min-1, and V1 = 1.08 × 103 ± 195 mL/kg.  
 
2.3.6.2.  Mouse subcutaneous injection 
 
The mice brain and plasma concentration profile was shown in Figure 2-10. The 
mice AUCbrain10 -180 min and AUCplasma10 -180 min were estimated at 150 min·mg/L and 36.9 
min·mg/L, respectively by noncompartmental analysis of the naïve pooled sparse 
sampling data using WinNonlin 5.2 NCA Model 200 with Linear Interpolation setting. 
Thus the mice brain to plasma AUC ratio was estimated at 4.07. In addition, the mice 
subcutaneous clearance was estimated to be 1.16 L/min/kg. 
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Figure 2-7. Metabolites of EDL-291 in rat plasma and feces 
 
EDL-291 metabolites from both phase I and phase II xenobiotic metabolism are found in plasma and feces of male SD rats that 
received intravenous dosing. 
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Table 2-3. Pharmacokinetic parameters of EDL-291 in male SD rats after oral gavage 
 
Subject CLoral (mL/min/kg)
Vdz, oral 
(L/kg) 
Terminal t1/2 
(min) 
Cmax 
(ng/mL)
tmax 
(min) 
AUCpo, 0-∞ 
(min·mg/L
) 
No. 1 492 93.6 132 504 40 81.2 
No. 2 510 52.4 71.3 457 20 78.5 
No. 2 740 65.4 61.3 239 100 54.0 
No. 4 486 82.6 118 599 40 82.4 
No. 5 409 56.9 96.5 689 40 97.8 
Geometric Mean 517 68.5 91.9 - - 77.4 
CV (%) 23.7 24.8 31.2 - - 20.0 
Median - - - 504 40 - 
Range - - - 450 80 - 
 
Note: Bioavailablity (F) = ( AUCpo, 0-∞ / Dosepo ) / ( AUCiv, 0-∞ / Doseiv) × 100%= ( 77.4 / 40 ) / ( 47.8 / 10 ) × 100% = 40.4 % 
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Figure 2-8. Brain and plasma concentration-time profile after 10 mg/kg intravenous bolus injection to SD rats  
 
Plasma: n = 5 at 5 min, 360 min, and 1440 min; n = 1 at 600 min; n = 6 at all other time points. Brain: n = 5 at 20 min, n = 2 at both 90 
min and 180 min. The error bars are standard deviations. 
Plasma 
Brain 
AUCbrain/AUCplasma20-180min = 14.0 
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Figure 2-9. Simultaneous fitting of rat brain and plasma concentration after 10 mg/kg intravenous bolus injection to the 
three-compartment user-defined model
Brain 
Plasma 
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Figure 2-10. Brain and plasma concentration-time profile after 50 mg/kg subcutaneous injection to mice 
 
Plasma: n = 1 at 30 min; n = 2 at all other time points. Brain: n = 2. The error bars are standard deviations. 
AUCbrain/AUCplasma10-180min = 4.07 
Brain 
Plasma 
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2.4.  Discussion  
 
 
Pharmacokinetic study is an integral part of the current drug development 
paradigm, playing an important role in various developmental stages. In the early drug 
development process, information obtained from pharmacokinetic study can provide 
valuable feedback for lead optimization and drug candidate selection [98]. The subject of 
the preclinical pharmacokinetics investigation presented in this chapter is the 
tetrahydroisoquinoline analog EDL-291, a result from DMPK-guided structure 
modification (i.e., blocking the metabolic hot spots and lowering cLogP) of lead 
compound EDL-155. 
 
As expected, total body clearance of EDL-291 in male SD rats (209 mL/min/kg) 
is 39% lower than that of EDL-155 (343 mL/min/kg). However, the former value is still 
almost 4 times higher than rat hepatic blood flow (55.2 mL/min/kg) and approaches 
cardiac output (296 mL/min/kg) [99]. For most drugs, the liver and kidney are the two 
most important eliminating organs. Therefore, total clearance (CL) can usually be 
approximate by hepatic clearance (CLh) plus renal clearance (CLr) (Figure 2-11). The 
renal clearance of EDL-291 can be ignored, since the fraction excreted unchanged in 
urine (fe) is only 0.012. Hepatic clearance cannot be larger than liver blood flow (Qh) 
since the hepatic extraction ratio (ERh) cannot be larger than 1. So the elimination of 
EDL-291 far exceeds the capacity of liver. Thus, there must be either some experimental 
artifacts which can lead to overestimating total clearance of EDL-291 or some 
extrahepatic mechanisms that contribute substantially to the elimination. 
 
The first extrahepatic mechanism deserving consideration is the pulmonary 
metabolism [100-102]. The lung contains various CYP450 enzymes as well as phase II 
drug metabolism enzymes [103-108]. It has the potential of metabolizing many foreign 
chemicals to a vast array of metabolites with different pharmacological and toxicological 
properties [100, 102, 109, 110]. Intravenously dosed drugs are subject to pulmonary 
metabolism before entering the liver. Since lungs accept total cardiac output, which is 5 
times higher than hepatic blood flow in rats, if the pulmonary extraction ratio is same as 
hepatic extraction ratio, the rat lung clearance could be 5 times higher than the hepatic  
 
 
                                               CL = CLh + CLr 
 
 
 
                        
                            CLh ≈CL-CLr              CLr=fe*CL 
                                  =Qh*ERh < Qh 
 
 
Figure 2-11. The usual relationship between total body clearance (CL), hepatic 
clearance (CLh), renal clearance (CLr), and liver blood flow (Qh) 
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clearance. As evidenced by the pulmonary microsomal stability experiment, EDL-291 is 
susceptive to pulmonary metabolism. The hot-spots for pulmonary metabolism are the 
methoxy groups in A-ring and C-ring since modification of these groups can increase the 
stability to pulmonary microsomes. 
 
Another important extrahepatic mechanism is metabolism or chemical 
degradation in the blood. Various drug metabolizing enzymes are located in either blood 
cells or plasma, and contribute to the elimination of dozens of structurally diverse drugs 
[111, 112]. Metabolism and degradation in blood is apparently not limited by the hepatic 
blood flow. However, the whole blood incubation experiment demonstrated that 
EDL-291 is stable for 3 hr in blood. Thus the contribution of blood 
metabolism/degradation to total body clearance of EDL-291 is negligible. 
 
A well-known artifact that can cause extraordinarily high clearance value is drug 
accumulation in erythrocytes [113]. Clearance is defined as the volume of blood 
irreversibly cleared of drug per unit of time. The total clearance value can be calculated 
as the dose divided by AUC in blood. For most drugs, blood concentration is close to 
plasma concentration, and plasma is easier to handle. Thus clearance of a drug is usually 
calculated from plasma drug concentration data instead of the whole-blood concentration 
data. This common practice is also used in this study. However, if the compound is 
accumulated in erythrocytes, i.e., the blood concentration is higher than plasma 
concentration, the clearance will be overestimated. Since the result of the erythrocyte 
partitioning experiment showed that EDL-291 does not accumulate in erythrocytes, the 
high clearance is not caused by this artifact.  
 
 Therefore, the major contributor to the high clearance of EDL-291 is extensive 
lung metabolism. Measurement of the afferent-efferent arterial (pulmonary artery vs. 
aorta) concentrations in steady states during a long intravenous infusion can be used in 
future study to confirm this finding in vivo [100, 102]. Comparing AUC after intravenous 
or intra-aortic short-term infusion is more convenient method to examine effect of lung 
on drug disposition. However, in some case, lung tissue may act as a deep compartment, 
which drugs will bind to and will not be released before end of blood sampling [100, 
102]. The afferent-efferent concentrations measurement can assure that the binding sites 
in lungs are saturated after long infusion and thus will not mistakenly count lung 
retention as lung clearance. The lung clearance can be calculated as CLlung = CO* ERlung 
= CO * (Cpa - Caorta) / Cpa, where CLlung, ERlung , CO, Cpa and Caorta refer to lung clearance, 
lung extraction ratio, cardiac output, drug concentration in pulmonary artery and drug 
concentration in aorta in this method, respectively. The lung clearance is a well-known 
exception to additivity of organ clearance [102]. But the ratio CLlung/ CL can still be used 
to express the relative contribution of lung to the total clearance. 
 
It can be speculated that intra-arterial injection of EDL-291 will lead to higher 
systemic exposure by avoidance of pulmonary first-pass effect. According to principle of 
diffusion, brain exposure will also be increased. If EDL-291 is injected through a 
microcatheter [114] to the rat internal carotid artery branch that supplies blood to brain, 
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its brain exposure of will be further increased since almost all the injected compound will 
be presented to BBB without loss due to clearance by lung, liver or kidney.  
 
EDL-155 was included as a control in the above-mentioned pulmonary 
microsomal stability, whole blood stability, and erythrocyte partitioning experiments. The 
results suggest that blood metabolism/degradation and erythrocyte accumulation 
contributed to the high clearance value of that compound. 
 
Due to the difficulties in collecting CSF and the nature of early phase brain 
pharmacokinetic research, brain homogenate concentrations of EDL-291were measured 
in this study. AUCbrain/AUCplasma ratio of 14.0 in rats and 4.07 in mice indicates a high 
brain penetration of EDL-291. A three-compartment pharmacokinetic model was 
successfully developed to fit EDL-291 plasma and brain homogenate concentrations 
simultaneously using WinNonlin software.  
 
Plasma protein binding of EDL-291 is around 60% at 5 μg/mL and 10 μg /mL 
concentration levels. Lowered plasma protein binding may be one of the reasons for 
improved brain penetration since the fraction of free drug available for BBB diffusion is 
increased. The bioavailability of EDL-291 after oral gavage is 42%. This indicates that 
oral dosing is feasible for this compound. 
 
Both phase I and phase II metabolites of EDL-291 were found in plasma and 
feces. COMT, responsible for methylation of the A-ring catechol of EDL-155, might be 
able to convert the A-ring didemethylation metabolite of EDL-291 back to the 
monodemethylation metabolite. As reported before, the most abundant EDL-155 
metabolite is formed by C-ring hydroxylation [65]. In EDL-291 structure modification in 
C-ring seems to have successfully blocked that reaction. 
 
  In conclusion, preclinical pharmacokinetic studies of EDL-291 were conducted in 
mice and rats following intravenous, oral, and subcutaneous administrations. EDL-291 
demonstrated lower clearance and improved brain penetration compared to the last 
generation compound EDL-155. EDL-291 has a low fraction of renal elimination, but the 
total clearance is still higher than liver blood flow. The likely mechanism of this high 
clearance value is not the red blood cell distribution or metabolism/degradation in blood. 
EDL-291 is rapidly and extensively metabolized by the lung microsomes, indicating that 
lung metabolism may cause this phenomenon. 
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CHAPTER 3.    PHARMACOKINETICS OF EDL-323 
 
 
3.1.  Introduction 
 
As shown in Chapter 2, EDL-291 was extensively metabolized by the lung 
microsomes, and demonstrated high clearance. For developing an antiglioma agent with 
better in vivo stability, EDL-323, i.e., 4-chloro-3- (4- {2H,5H,6H,7H,8H- [1,3] dioxolo 
[4,5-g] isoquinolin-5-ylmethylphenyl) pyridine, a derivative of EDL-291, was 
synthesized in Dr. Duane Miller’s laboratory by modification of pulmonary metabolic 
“soft spots.” Chemical structure and selected physiochemical properties of EDL-323 are 
shown in Figure 3-1. 
 
As shown in Table 2-2, EDL-323 has higher stability to rat pulmonary 
microsomes when compared to EDL-291. The objective of the experiments in this 
chapter was to examine the in vivo pharmacokinetic properties of EDL-323 in rats 
following both intravenous and oral administrations, which were used to provide 
feedback information for further antiglioma drug development decisions.  
 
 
3.2.  Materials and Methods 
 
 
3.2.1.  Materials 
 
Ammonium acetate (ACS), HPLC grade acetonitrile and HPLC grade water were 
purchased from Fisher Scientific (Fair Lawn, NJ). Compounds EDL-323 and EDL-313 
(internal standard for EDL-323) were synthesized in Dr. Duane Miller’s laboratory. 
 
 
3.2.2.  LC/MS/MS method 
 
The LC/MS/MS system was composed of an Applied Biosystems Sciex (Foster 
City, CA) API 3000 tandem mass spectrometer, and Shimadzu (Columbia, MD) 
LC-10ADvp pumps with a LEAP (Carrboro, NC) HTS PAL autosampler. Data were 
processed using Analyst software 1.4.2. Chromatographic separation was performed 
using a Cadenza CD-C18 column (100 × 2.0mm, 3 μm, purchased from Silvertone 
Sciences, Philadelphia, PA). The mobile phase consisting of A (10mM NH4Ac in HPLC 
grade water, pH7.4) and B (acetonitrile) was delivered at 0.5 mL/min. The total run time 
was 3.5 min. Gradient elution began at 30% B and was held for 1 min, then increased to 
70% B over 1 min, decreased to 30% B over 1 min, and finished at 30% B for 0.5 min. 
 
The mass spectrometer was operated in positive ESI mode with the following 
parameters: ionspray voltage (IS) 1500 V, nebulizing gas (NEB) 14.0, curtain gas (CUR) 
14.0, source temperature (TEM) 550.0 °C, collision-activated dissociation (CAD) gas  
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Figure 3-1. Structure and selected physiochemical properties of EDL-323 
 
Exact mass and cLogP were calculatedd by ChemDraw Ultra 12.0 (CambridgeSoft 
Corporation, Cambridge, MA). All other values were calculated by Marvin Calculator 
Plugins (ChemAxon Kft., Hungary). 
 
  
Molecular Weight: 
378.85 
Exact Mass: 378.11 
cLogP: 4.44 
H-bond donor: 1 
H-bond acceptor: 4 
Rotable bonds: 3 
         PSA: 43.38Å2 
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7.0, declustering potential (DP) 76.0 V, focusing potential (FP) 150.0 V, entrance 
potential (EP) 10.0 V, collision energy 31.0 V, collision cell exit potential (CXP) 
18.00 V, deflector (DF) –200 V, channel electron multiplier (CEM) 2200 V, and turbo 
gas (GS2) 7.0 L/min.  
 
The MS/MS measurements were performed under MRM mode. The molecule 
ions [M + H] + selected in Q1 were subjected to collision-activated dissociation by N2 in 
the collision cell (Q2), and the product ions were monitored by scanning the third 
quadrupole (Q3). The monitored MRM transition values were 379.2→202.2 for EDL-323 
and 395.0→202.2 for EDL-313. 
  
 
3.2.3.  Animals  
 
Male Sprague-Dawley rats weighing between 250 and 275 grams were purchased 
from Charles River Laboratories (Wilmington, MA) and maintained in the animal facility 
of the UTHSC. All the rats (n = 4) bore both jugular and femoral vein catheters. The 
patency of catheters was maintained every other day with heparinized glycerol solution 
(500 IU heparin/mL final solution in 75% glycerol) according to vendor’s instructions. 
Rats were fed ad libitum on normal laboratory diet and water. A 12 hr light-dark cycle 
and ambient temperature of 25 °C were maintained. Rats were individually housed in 
regular plastic cages.  
 
 
3.2.4.  Drug solution  
 
EDL-323 was dissolved in sterile normal saline at 10 mg/mL concentration.  
 
 
3.2.5.  Pharmacokinetic sampling and processing  
 
EDL-323 was administered (10 mg/kg) to SD rats (n = 4) by intravenous bolus 
via the femoral vein catheter. Blood (100 µL) was collected into Microtainer® tubes with 
lithium heparin and plasma separation gel (BD, Franklin Lakes, NJ, Catalog # 365958) 
from the jugular vein catheter at timed intervals 2, 5, 15, 30, 45, 60, 75, 90, 120, 180, 
240, 360, 480, 600, 960, and 1440 min. Samples were centrifuged at 10,000 g, 4 °C for 2 
min. Plasma was stored at -80 °C until analysis.  
 
200 µL of ice-cold acetonitrile and 20 µL of IS (internal standard solution) were 
added to each of 50 μL plasma samples. The resulting mixture was vortexed and 
centrifuged at 10,000 g, 4 °C for 10 min. 10 µL of the supernatant was injected for 
LC/MS/MS analysis. 
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3.2.6.  Pharmacokinetics data analysis  
 
The clearance (CL), volume of distribution at steady state (Vdss), terminal 
half-life (t1/2), and area under the curve (AUCiv, 0-∞) were estimated by NCA Model 201 
with Linear Up/Log Down setting in WinNonlin 5.2. The last 3 data points with available 
concentrations were used for estimating terminal slope λz. The estimated individual 
pharmacokinetic parameters were then summarized by the built-in descriptive statistics 
tool in WinNonlin. 
 
 
3.3.  Results 
 
The plasma concentration versus time profile of EDL-323 (Figure 3-2) during the 
sampling period demonstrated rapid elimination. The secondary peak around 600 min 
after dosing could be a sign of enterohepatic recirculation. The pharmacokinetic 
parameters are shown in Table 3-1. 
 
 
3.4.  Discussion 
  
As expected, total body clearance of EDL-323 is 38% lower than that of 
EDL-291. However a pilot study showed that the brain penetration is dramatically 
reduced. Therefore, other structure modifications should be tried to obtain lower 
clearance but maintain the high brain penetration.  
 
A newer derivative EDL-355 showed higher brain penetration and in vitro 
efficacy in another pilot study. Thus EDL-355 will be the next candidate to be used in 
future pharmacokinetics investigation. 
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Figure 3-2. Plasma concentration-time profile after 10 mg/kg intravenous bolus 
injection of EDL-323 
 
N = 3 at 2 min; n =4 at all the other data points. The error bars are standard deviations. 
 
 
 
 
Table 3-1. Pharmacokinetic parameters of EDL-323 in male SD rats after 
intravenous bolus injection 
 
Subject CL (mL/min/kg) 
Vdss 
(L/kg) 
Terminal t1/2
(min) 
AUCiv, 0-∞ 
(min·mg/L) 
No. 1 114 9.00 1.07 × 103 87.5 
No. 2 136 19.8 834 73.6 
No. 3 127 9.07 776 78.5 
No. 4 155 7.48 373 64.6 
Geometric Mean 132 10.5 713 75.6 
CV (%) 12.7 50.3 38.0 12.5 
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CHAPTER 4.    MECHANISM OF ACTION STUDY OF EDL-291 
 
 
4.1.  Introduction 
 
 Many EDL series of novel tetrahydroisoquinoline analogs show antiproliferative 
activity on glioma cells. Since they were discovered by serendipity, the mechanism of 
action was unknown for these compounds before the start of this dissertation research 
project. Currently, a drug candidate with unknown mechanism is not likely to get FDA 
approval [68]. Therefore, a preliminary mechanism of action study was included in this 
project. EDL-291 was selected as a model compound for this study. 
 
 There are five major modes of cell death induced by chemotherapy: apoptosis, 
autophagic cell death, necrosis, mitotic catastrophe, and senescence [74]. Among these, 
apoptosis is the most well-known way of cell death after anticancer drug treatment. 
Therefore, the role of apoptosis machinery on the activity of EDL-291 was the focus of 
this study. 
 
 
4.2.  Materials and Methods 
 
 
4.2.1.  Cell cultures 
 
 Human glioma cell line U-87MG was purchased from American Type Culture 
Collection (ATCC, Manassas, VA). Culture medium for this cell line was Basal Medium 
Eagle with Earle's salts (BME, Mediatech, Manassas, VA) supplemented by 10% fetal 
bovine serum (FBS, Sigma, St. Louis, MO), 2.2 mg/mL sodium bicarbonate (Sigma, St. 
Louis, MO), 50 IU/mL penicillin (Invitrogen, Carlsbad, CA), 50 µg/mL streptomycin 
(Invitrogen, Carlsbad, CA), and 50 µg/mL streptomycin (Invitrogen, Carlsbad, CA). 
Human glioma cell line U251 was obtained from the National Cancer Institute (NCI, 
Frederick, MD). Culture medium for this cell line was RPMI 1640 (Invitrogen, Carlsbad, 
CA) supplemented by 10% fetal bovine serum, 100 IU/ mL penicillin, and 100 µg/mL 
streptomycin. These cell lines were maintained in 75 cm2 culture flasks (Corning Life 
Science, Lowell, MA) in a 37 °C incubator (NuAire, Plymouth, MN) containing a humid 
5% CO2 atmosphere and passaged in 1:4 ratio after being washed by Dulbecco's 
phosphate-buffered saline without calcium and magnesium (D-PBS, Invitrogen, 
Carlsbad, CA) and dislodged by 0.25% trysin-EDTA (Mediatech, Manassas, VA) once 
they reached 80% confluence. 
 
 
4.2.2.  Cell proliferation assay with caspase inhibitors or mitochondrial permeability 
transition (MPT) inhibitors 
 
 EDL-291 was synthesized in the laboratory of Dr. Duane Miller. CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation (MTS) assay kit was purchased from 
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Promega (Madison, WI). Pan-caspase inhibitor Z-VAD-fmk was purchased from Enzo 
Life Sciences (Plymouth Meeting, PA). Caspase-3/7 inhibitor Z-DEVD-fmk was 
purchased from R&D Systems (Minneapolis, MN). Caspase-8 inhibitor Z-IETD-fmk and 
caspase-9 inhibitor Z-LEHD-fmk were purchased from Tocris (Ellisville, MO). MPT 
inhibitor decylubiquinone (dUb) was purchased from Enzo Life Sciences. 
 
 The antiproliferative effect of EDL-291 with or without inhibitors was determined 
by using MTS assay according to manufacturer’s direction. In brief, U-87MG and U251 
cells were seeded at 5 × 103 cells/well in 96-well flat-bottomed plates (Corning Life 
Science, Lowell, MA) and grown overnight in 200 µL aforementioned medium with 10% 
FBS in a 37 °C incubator containing a humid 5% CO2 atmosphere. EDL-291 was 
dissolved in sterile normal saline to get a 50mM stock solution, while caspase inhibitors 
and dUb were dissolved in DMSO (Sigma, St. Louis, MO) to make stock solutions. 
These stock solutions were spiked into the aforementioned medium with 2% FBS to get 
drug-containing media. The DMSO concentrations were kept at less than 0.25%. Control 
media were made by spiking DMSO to final concentrations that matched those in the 
drug-containing media. Then the medium in the 96-well plate was replaced by 200 
µL/well drug-containing medium or control medium. After the cells were incubated for 
96 hr in 37 °C, 5% CO2, the consumed media were replaced by 100 µL/well fresh media 
with 2% FBS. Then 20 µL/well MTS [3- (4, 5-dimethylthiazol-2-yl) -5- (3-
carboxymethoxyphenyl) -2- (4-sulfophenyl) -2H-tetrazolium] - PMS (phenazine 
methosulfate) mixtures were added. After 1 hr incubation in 37 °C, 5% CO2, the 
absorbance at 450 nm was measured using a DTX 880 multimode detector (Beckman 
Coulter, Fullerton, CA). The absorbance of medium-only wells was subtracted from 
reading of control or treated wells. The viability of control cells was considered to be 
100%. 
 
 
4.2.3.  Caspase 3/7 activity assay 
 
 U-87MG and U251 cells were seeded at 5 × 103 cells/well in 96-well 
flat-bottomed plates and grown overnight in 200 µL of the aforementioned medium with 
10% FBS in a 37 °C incubator containing a humid 5% CO2 atmosphere. Then the 
medium in the 96-well plate was replaced by 200 µL/well 2% FBS medium containing 
10µM EDL-291 with or without dUb or control medium. After the cells were incubated 
for 60 hr in 37 °C, 5% CO2, the consumed media were replaced by 100 µL/well fresh 
media with 2% FBS. The luminogenic substrate and luciferase-containing buffer from the 
Capase 3/7 Glo kit were mixed to prepare the reagent right before use. 100 µL pre-
warmed reagent was added to each well, and then the plate was put on a plate shaker for 
30 min. After 60 min incubation in room temperature, the luminescence was measured by 
DTX 880 multimode detector. The luminescence of medium only wells was subtracted 
from reading of the control or treated wells. The blank subtracted luminescence readings 
(RLU) were further normalized by absorbance at 450 nm, which was obtained from the 
aforementioned MTS assay of duplicate wells. 
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4.2.4.  Luminex assay of activated caspase-3 and poly (ADP-ribose) 
polymerase (PARP) 
 
 Human apoptosis 3-plex Luminex kit, MultiScreenHTS BV filter plates, and 
vacuum manifold were purchased from Millipore (Billerica, MA). Complete MiniTM 
protease inhibitor cocktail tablets were purchased from Roche Diagnostics (Indianapolis, 
IN). Phosphate-buffered saline (PBS) was purchased from Invitrogen (Carlsbad, CA). 
U-87MG and U251 cells were cultured in a 200 µL/well 2% FBS medium containing 
10µM EDL-291 or control medium, the same as described from the caspase 3/7 activity 
assay. After the cells were incubated for 72 hr or 96 hr, the consumed media were 
aspirated. ¼ tablet of Complete MiniTM protease inhibitor was added to the ice-cold 
Beadlyte cell signaling universal lysis buffer in the Luminex kit right before use. Then 30 
µL/well lysis buffer was added, and the plates were shaken for 20 min at 4 °C. The lysate 
was transferred to a pre-wetted MultiScreen HTS BV filter plate, and then was filtered by 
centrifugation at 500 g for 5 min. The filtrate from the wells of the same treatment group 
was combined and diluted by equal volume of PBS. 25 μL/well 1 × 3-plex [human 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), activated caspase-3, and PARP] 
bead suspension and 25 μL/well diluted filtrate were added into a new MultiScreen 
HTS BV filter plate pre-wetted by using vacuum manifold. The filter plate was incubated 
on a plate shaker overnight at 4 °C while protected from light; then the liquid was 
removed and beads were washed by using vacuum manifold. 25 μL/well of 1 × Beadlyte 
biotinylated reporter was added to beads, and then the filter plate was incubated on a 
plate shaker for 1 hr at room temperature. After removal of the liquid by vacuum, 25 μL 
1:25 diluted Strep-PE was added to each well; then the filter plate was incubated on a 
plate shaker for 30 min at room temperature. The liquid was removed again by vacuum. 
The beads were resuspended by 100μl assay buffer and then analyzed on Luminex 200 
system (Luminex, Austin, TX).The raw data was processed by Millipore Beadview 
multiplex data analysis software, and the activated caspase-3 and PARP level were 
normalized to GAPDH level. 
 
 
4.2.5.  Phase contrast and fluorescence microscopy 
 
 U-87MG and U251 cells were seeded at 5 × 103 cells/well in 96-well flat-
bottomed plates and grown overnight in 200 µL of the aforementioned medium with 10% 
FBS in a 37 °C incubator containing a humid 5% CO2 atmosphere. Then the medium in 
the 96-well plate was replaced by 200 µL/well 2% FBS medium containing 10µM 
EDL-291 or control medium. After the cells were incubated for 60 hr in 37 °C, 5% CO2, 
and pictures were taken under a phase contrast microscope. Following this, the cells were 
washed by PBS, fixed by 1% paraformaldehyde for 10 min, and then stained with 
Hoechst 33342 for 20 min at room temperature before pictures were taken under an 
Eclipse 80i fluorescence microscope (Nikon, Melville, NY).  
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4.2.6.  Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay  
 
 TUNEL assay was performed using a BD Pharmingen APO-BRDU kit (BD 
Biosciences, San Jose, CA) according to manufacturer’s direction. Briefly, 2.34 ×106 
U-87MG or U251 cells were seeded in150 cm2 culture flasks (Corning Life Science, 
Lowell, MA) using the aforementioned 10% FBS media. After overnight incubation in 37 
°C, 5% CO2 incubator, the consumed media were changed to drug-containing or control 
2% FBS media. After 60 hr treatment, the floating cells and trypsinized adherent cells 
from the same treatment were collected together. These cells were washed by PBS, fixed 
by 1% paraformaldehyde, and permeabilized by 70% ethanol. Then the DNA breaks were 
labeled by terminal deoxynucleotidyltransferase (TdT) catalyzed addition of bromolated 
deoxyuridine triphosphates (Br-dUTP), followed by staining with fluorescein 
isothiocyanate (FITC) conjugated BrdU antibody. The samples were loaded to a LSR II 
flow cytometer (BD Biosciences) using 488 nm laser, and the data were processed by 
FACSDiva software. 
 
 
4.3.  Results 
 
 
4.3.1.  Effect of caspase inhibitor 
 
 As shown in Figure 4-1, antiproliferative effect of EDL-291 can be partially 
reversed by pan-caspase inhibitor Z-VAD-fmk and caspase-3/7 inhibitor Z-DEVD-fmk. 
However, caspase-8 inhibitor Z-IETD-fmk and caspase-9 inhibitor Z-LEHD-fmk cannot 
reverse the effect of EDL-291. 
 
 
4.3.2.  Effector caspase activation 
 
 As shown in Figure 4-2, 60 hr 10µM EDL-291 treatment can increase the activity 
of caspase-3/7 in U-87MG and U251 cells. In Luminex assay, the activated caspase-3 
protein as well as its product cleaved PARP are increased after 72 hr EDL-291 treatment 
(Figure 4-3).  
 
 
4.3.3.  Cell and nucleus morphology 
 
 No change in cell morphology was found in U-87MG and U251 cells treated by 
10µM EDL-291 for 60 hr (Figure 4-4). No nucleus change was found by Hoescht 33342 
staining at the same time point (Figure 4-5).  
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Figure 4-1. Antiproliferative effect of EDL-291 can be partially reversed by 
pan-caspase inhibitor (panel A) and caspase-3/7 inhibitor (panel B), but not by 
caspase-8 and 9 inhibitors (panel C)  
 
U-87MG and U251 human glioma cells were treated by 10 μM EDL-291 with or without 
caspase inhibitor for 96 hr. The cell viability was measured by MTS assay using Promega 
CellTiter AQueous 96 kit. The absorbance of medium-only wells was subtracted from 
reading of control or treated wells. The viability of control cells was considered to be 
100%. The data shown here are representative results of 3 independent experiments. The 
error bars are standard deviation of 3 replicates in the same treatment condition. 
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Panel C 
 
 
Figure 4-1. (Continued) 
  
0
20
40
60
80
100
120
Control EDL-291
(10µM)
EDL-291 (10µM)+
8-inh (50µM)
EDL-291 (10µM)+
9-inh (50µM)
C
el
l P
ro
lif
er
at
io
n 
(1
00
%
)
U-87MG Cells
 60 
 
 
Figure 4-2. EDL-291 can increase caspase-3/7 activity in human glioblastoma cells 
 
U-87MG and U251 human glioma cells treated by 10 μM EDL-291 for 60 hr were 
subjected to caspase-3/7 activity assay using Promega Caspase-Glo 3/7 kit. The data 
shown here are representative results of 3 independent experiments. The error bars are 
standard deviation of 3 replicates under the same treatment condition. 
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Figure 4-3. Increase of activated caspase-3 and its product, cleaved poly 
(ADP-ribose) polymerase (PARP) after EDL-291 treatment as measured by 
Luminex multiplex immunoassay 
 
U-87MG and U251 human glioma cells were treated by EDL-291 for 72 hr. The cell 
lysate was analyzed using Millipore Human Apoptosis 3-Plex kit and Luminex 200 
instrument. 
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Figure 4-4. Cell morphology checked by phase contrast microscopy  
 
U-87MG and U251 human glioma cells treated by 10 μM EDL-291 for 60 hr were 
pictured under a phase contrast microscope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
U-87MG Cells U251 Cells 
EDL-291 
(10μM) 
 63 
 
 
 
Figure 4-5. Nucleus morphology checked by florescent microscopy after Hoescht 
staining  
 
U-87MG and U251 human glioma cells treated by 10 μM EDL-291 for 60 hr were 
stained with Hoechst 33342 and pictured under Eclipse 80i fluorescence microscope. 
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4.3.4.  DNA fragmentation 
 
 Increase of DNA fragmentation was found in U251 cells after 60 hr EDL-291 
treatment as indicated by the TUNEL result, while change of DNA fragmentation in 
U-87MG cells under same condition is minor (Figure 4-6). 
 
 
4.3.5.  Effect of MPT inhibitors  
 
 As shown in Figure 4-7, the antiproliferative effect of EDL-291 can be enhanced 
rather than reversed by MPT inhibitor dUb. The caspase-3/7 activation after EDL-291 
treatment also can be enhanced by dUb. 
 
 
4.4.  Discussion 
 
 Since antigloma activity of the EDL series of compounds was an unexpected 
output in a HCV drug screening project [72]. Efforts were made by molecular docking 
and various ligand binding assays to “fish” the putative molecular target directly but with 
no success. Therefore, a less ambitious approach was taken, which was to first investigate 
their effect of EDL series of compounds on cell death pathways. A preliminary 
evaluation of the effect of EDL-291 on human glioma cell apoptosis machinery was 
performed in our laboratory.  
 
 The investigation was begun with caspase inhibitor assay. The pan caspase 
inhibitor can significantly reverse the effect of EDL-291 on both U-87MG and U251 
human glioma cell lines, which indicates that caspases contribute to the effect of 
EDL-291. Since pan caspase inhibitor also can also inhibit caspases not related to 
apoptosis, a further assay with a specific inhibitor of apoptosis effector caspases-3/7 was 
performed, and then followed by direct measurement of caspases-3/7 activity by 
luminogenic substrate. The results confirmed activation of these effector caspases and 
their involvement in the antiproliferative effect of EDL-291. An additional Luminex 
assay also supported this finding. 
 
 Caspases-3/7 activation is a biochemical hallmark of apoptosis [115]. Cell and 
nucleus morphology, as well as DNA fragmentation, were evaluated after 60 hr of 
EDL-291 treatment, the same time point used in the caspases-3/7 activity assays. 
However, no morphology change of cell or nucleus was found, and the increase of DNA 
fragmentation was minor in U-87MG. The explanation could be that there is some time 
delay between caspase activation and those downstream events. 
 
As described in 1.3.3.1., effector caspases activation is catalyzed by initiator 
caspases. Caspase-8 and -9 are the initiator caspases for the extrinsic and intrinsic 
pathways of apoptosis, respectively (Figure 4-8). Thus specific caspase-8 and -9 
inhibitors assay was performed to identify the route of apoptosis. But none of these 
inhibitors could reverse the effect of EDL-291 under the condition used. 
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Figure 4-6. DNA fragmentation assay results from flow cytometric TUNEL 
 
U-87MG or U251 cells treated by 10 μM EDL-291 for 60 hr were labeled by Br-dUTP, 
then stained with FITC-conjugated BrdU antibody. X-axis is the cell count and Y-axis is 
the intensity of FITC fluorescence (520 nm) that is proportional to amount of Br-dUTP 
incorporation. The apoptotic cells incorporate more Br-dUTP because of existence of 
abundant 3’-OH DNA ends. As shown in the figure, the percentages of apoptotic cells are 
quantified as percentages of cells at the right side of P3 gate. The main peaks correspond 
to the non-apoptotic cell population. The samples were measured by BD LSR II flow 
cytometer using 488 nm laser, and the data was processed by FACSDiva software. 
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Figure 4-7. Antiproliferative effect of EDL-291 and caspase 3/7 activation can be 
enhanced, rather than reversed by decylubiquinone (dUb) 
 
Upper panel: U-87MG and U251 human glioma cells were treated by EDL-291 with or 
without 2 μM dUb for 96 hr. The viable cell number was measured by MTS assay using 
Promega CellTiter AQueous 96 kit. The reading was subtracted by media blank and then 
normalized by the control. Lower panel: U-87MG and U251 human glioma cells treated 
by EDL-291 with or without 2 μM dUb for 60 hr were subjected to caspase-3/7 activity 
assay using Promega Caspase-Glo 3/7 kit. The data shown here are representative results 
of 3 independent experiments. The error bars are standard deviation of 3 replicates under 
the same treatment condition.  
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Figure 4-8. Apoptosis pathways and proposed model of EDL-291’s effect in 
glioma cells 
 
The extrinsic, intrinsic, caspase-independent and endoplasmic reticulum stress-induced 
apoptosis pathways are all shown in this figure. The proposed model of EDL-291’s effect 
in glioma cells are shown in red color. 
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 Since most chemotherapeutic drugs induce apoptosis via intrinsic route [75, 76], 
and opening of mitochondrial permeability transition (MPT) pore could be an upstream 
event in this route [116], the MPT pore inhibitor decylubiquinone (dUb) was used to 
investigate if MPT is involved in the effect of EDL-291. This led to a surprising finding: 
dUb enhances, instead of reverses, EDL-291’s effect on human glioma cells. Further 
evaluation by effector caspase activity assay suggests that this effect is related to 
enhancement of caspase-3/7 activation. 
 
 A recent publication about antiglioma activity of XIAP inhibitor embelin provides 
a potential explanation of this finding [117]. Chemical structure of dUb is similar with 
that of embelin (Figure 4-9). Therefore, dUb may also be a XIAP inhibitor and is capable 
of de-inhibiting caspases. Further investigation by ligand binding assay is necessary to 
test this hypothesis.  
 
 The upstream apoptotic pathway that leads to effector caspase-3/7 activation was 
not successfully identified by the caspase-8/9 inhibitor assay in this study. A direct 
caspase-8/9 activity assay by either luminogenic substrate or Luminex assay may be 
helpful to solving this problem.  
 
 It is also possible that capsase-4 (counterpart of murine caspase-12), an 
uncommon initiator caspase activated after ER stress [86], is responsible for the 
caspase-3 activation after EDL-291 treatment(Figure 4-8). When ER homeostasis is 
disrupted by various stimuli, unfolded proteins are accumulated in the ER, which initiate 
ER stress response to enhance protein folding capabilities, reduce new protein synthesis, 
and clear malformed proteins. But when this response is prolonged, it will lead to cell 
death. During ER stress, ER associated procaspase-4 was released from GRP78. The 
prolonged stress will also cause ER to release its calcium storage and thus increase 
cytosolic Ca2+ concentration. These events enable cleavage of procaspse-4 by Ca2+ 
dependent cysteine proteases calpain [79, 118]. Procapase-3 then can be activated by 
caspase-4 directly [87]. Multiple reports already showed that caspase-4 was activated 
during ER stress in malignant human glioma [79]. Examples of drugs inducing apoptosis 
via the ER stress pathway in glioma or other cancer cells include, sarco/endoplasmic 
reticulum ATPase inhibitors (celecoxib, curcumin and THAP), flavonoids, N-linked 
glycosylation inhibitors (tunicamycin), Golgi disruptors (brefeldin A), and proteasome 
inhibitors (bortezomib) [79]. 
 
There is an unusual 60 hr time delay between beginning of EDL-291 treatment 
and peaking of caspase-3 activity. This delayed apoptosis has also been observed after 
radiation-induced mitotic catastrophe [119]. However, lack of nucleus morphology 
change in the Figure 4-5 indicates that mitotic catastrophe did not happen. The 
hypothesis that a prolonged ER stress response precedes the onset of apoptosis caused by 
EDL-291 can therefore also help explain that time delay. 
  
ER stress can lead to both apoptosis and autophagy [77]. The decrease of cell 
density in treated wells in Figure 4-4 also suggests that other cell death pathways, such 
as autophagy, may already have taken place before the culmination of apoptosis, which  
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Figure 4-9. Chemical structures of decylubiquinone and embelin 
  
Decylubiquinone Embelin (XIAP inhibitor) 
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should happen after that 60 hr caspase-3 peak time. Our collaborating laboratory has 
recently reported that EDL-155 can cause autophagy in Y79 retinoblastoma cells [120]. 
And after EDL-155 treatment, autophagosome-like double-membrane-bound large 
vacuoles in cytoplasm were found in rat C6 glioma cells but not in rat normal astrocytes 
[66]. As indicated by green fluorescence mitochondrial stain, the mitochondrial 
membranes have coalesced into those large vacuoles in EDL-155 treated C6 cells [66], 
suggesting mitophagy, i.e., specific autophagic elimination of mitochondria may have 
occurred [121]. A pilot study in our laboratory shows autophagy inhibitor 
3-methyladenine can partially reverse the effect of EDL-291 on human glioma cells. 
Therefore, EDL-291 may cause ER stress, and the latter leads to both apoptosis and 
autophagic cell death. A putative model of the effect of EDL-291 as well as relevant 
apoptosis pathways are shown in Figure 4-7. Further investigation using ER stress 
inhibitor, caspase-4 inhibitor and calpain inhibitor is needed to check the validity of this 
model. 
 
 In order to find clue about the target of EDL series of compounds, a literature 
search on mechanisms of action of other isoquinoline derivatives with antiglioma activity 
was conducted. Tetrahydropapaveroline, the structure of which is very similar to that of 
EDL-155, can cause oxidative DNA damage and JNK/MAPK mediated cell death in rat 
C6 glioma cells [122]. However, this mechanism depends on the catechol moieties in the 
structure of tetrahydropapaveroline. The catechol moiety can be found in structure of 
EDL-155 but not in the structure of EDL-291. The fact that EDL-291 has lower EC50 
than EDL-155 is apparently against this oxidative damage mechanism.  
 
 Papaverine can also inhibit growth of rat C6 glioma cells [123]. There are two 
possible mechanisms: increase of intracellular cAMP concentration by inhibiting 
phosphodiesterase (PDE) 3 and 4 [124, 125], and inhibition of mitochondria respiration 
[126]. Increased cAMP level is a proapoptotic signal in multiple cancer cell lines and 
may promote differentiation of astrocyte, while low levels of cAMP promote glioma 
formation in neurofibromatosis-1 (NF1) genetically engineered mice [127]. Another 
PDE4 inhibitor rolipram also promotes differentiation and apoptosis in A-172 human 
glioma cell line [128]. However, tetrahydropapaverine and tetrahydropapaveroline, 
structures of which closely mimic those of EDL-291 and EDL-155, respectively, have 
very low PDE inhibitor activity [125]. Papaverine, tetrahydropapaverine and 
tetrahydropapaveroline are all inhibitors of mitochondrial electron transport chain 
complex I [129, 130]. In the other hand, dUb, as a substrate of complex I, can attenuated 
the inhibition caused by the potent complex I inhibitor rotenone [131]. Therefore, at least 
for EDL-291, the complex I inhibition could not be plausible mechanism, because that 
mechanism is contradict to the observation in this study that dUb can enhance EDL-291’s 
effect. 
 
 Another opium derived tetrohydroisoquinoline drug noscapine has antiglioma 
effect both in vitro [132] and in vivo [133]. As a microtubule-interfering agent, noscapine 
induces mitotic catastrophe followed by apoptosis [132]. But since no multinucleated 
glioma cells were found after EDL-291 and EDL-155 treatment, microtubule-interfering 
is not a plausible mechanism of the EDL series of compounds. 
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 In addition, tetrahydroisoquinoline alkaloid trabectedin also has antiglioma 
activity in vitro [134]. Its antitumor mechanism is not fully understood. It is believed to 
be able to bind the minor groove of DNA through the two fused tetrahydroisoquinoline 
rings [135], which is absent in the structures of EDL series of antiglioma 
tetrahydroisoquinoline derivatives.  
 
 Many other tetrahydroisoquinolines with various mechanisms of action show 
activities against other types of cancer cells [136]. Tarby et al. reported a 
4-phenyl-tetrahydroisoquinoline lead series has antiproliferative effect on human ovarian 
cancer cells. They may act as inhibitor of human mitotic kinesin Eg5 [137]. Again, the 
lack of multinucleated glioma cell after treatment ruled out this mitotic related 
mechanism as the antiglioma mechanism of the EDL compounds. A series of 
tetrahydroisoquinoline-based hydroxamic acid derivatives was discovered by Zhang et al. 
as HDAC inhibitor with in vivo antitumor potency in a human breast carcinoma 
xenograft model [138]. The carboxamide group is part of the pharmacophore [139], but 
this group is not presented in the structures of EDL-291 and EDL-155. A series of 
tetrahydroisoquinoline amide substituted phenyl pyrazoles are reported to be selective 
Bcl-2 inhibitors [140]. However, no evidence of direct interaction between EDL-291 and 
Bcl-2/Bcl-XL was found in a pilot study in our laboratory using Luminex and 
fluorescence polarization techniques.  
 
 In conclusion, EDL-291 activates caspase-3/7 and PARP cleavage. The upstream 
event before caspase-3 activation could be ER stress. The molecular target of EDL-291 is 
still unknown. As an enhancer of EDL-291 caused capase-3/7 activation, dUb could be a 
candidate as a companion drug of EDL-291 analogs in combination therapy of glioma. 
  
 72 
CHAPTER 5.    SUMMARY 
 
 
Malignant glioma is a relative uncommon but extremely deadly disease. Each 
year, more than 18,000 people are diagnosed with malignant glioma in the USA. Despite 
advances in brain tumor diagnosis and treatment in the last decades, patients with 
malignant gliomas, especially glioblastoma, still have a poor prognosis. Novel antiglioma 
drugs are urgently needed, as chemotherapy has been established as part of standard care 
for these dreadful diseases. 
 
A novel series of tetrahydroisoquinoline derivatives with potent antiproliferative 
activity against human glioma cells was identified in The University of Tennessee Health 
Science Center by our collaborating laboratories as a result of scientific serendipity. 
Further investigations were performed in the effort to develop a latest addition to the 
current antiglioma arsenal from these compounds. Pharmacokinetics plays an important 
role in the current drug discovery and development paradigm. EDL-291, a result from 
DMPK-guided structure modification of last generation antiglioma 
tetrahydroisoquinoline derivative lead compound EDL-155, is the subject of preclinical 
pharmacokinetic characterization in this dissertation project. 
 
In male Sprague Daley rats, after 10 mg/kg intravenous injection, total body 
clearance (CL) and apparent volume of distribution at steady state (Vdss) of EDL-291 
were 209 mL/min/kg (CV 23.7%) and 32.5 L/kg (CV 46.6%), respectively. 1.2% of 
dosed EDL-291 was found in urine (fe) over the 24 hr post-dose period. Plasma protein 
binding of EDL-291 at 5 μg/mL and 10 μg/mL concentration levels was 60.0% and 
54.4%, respectively, in the rat plasma. The bioavailability (F) after oral gavage was 
40.4%, which indicates this compound is orally available. 
 
The ratio of the EDL-291 brain area under concentration curve (AUC) to plasma 
AUC between 20 -180 min after intravenous injection in SD rats was 14.0. The 
brain/plasma AUC ratio at 10 - 180 min after 50 mg/kg subcutaneous injection to 
C57BL/6J mice was estimated at 4.07. Thus EDL-291 has high brain penetration in both 
rats and mice. The rat plasma and brain concentration of EDL-291 can be fitted 
simultaneously into a three-compartment model consisting of one brain compartment and 
two peripheral compartments by using WinNonlin® software version 5.2. 
 
CL of EDL-291 was 39% lower than that of EDL-155 but was still almost 4 times 
higher than rat hepatic blood flow, while the small fe value indicates that renal CL was 
minimal. Three possible causes were examined to decipher this phenomenon. EDL-291 is 
stable in whole blood, thus metabolism or chemical degradation in blood is not a reason. 
EDL-291 is also not accumulated in red blood cells, thus the high CL is not an artifact 
caused by plasma sampling. On the other hand, this compound is susceptible to 
pulmonary microsomal metabolism. Considering that lungs accept total cardiac output, 
the major contributor to the high CL of EDL-291 is extensive lung metabolism. 
 
EDL-323, an analog of EDL-291 with higher stability to pulmonary microsomes, 
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was selected as the subject of an in vivo pharmacokinetic study. As expected, CL of 
EDL-323 was 38% lower than that of EDL-291. However, a pilot study showed that the 
brain penetration is dramatically reduced. Thus, further structural modifications are 
required to achieve both reduced clearance and enhanced brain penetration.  
 
Since antigloma activity of EDL compounds was an unexpected discovery in a 
HCV drug screening project at our collaborating groups, their mechanism of action was 
unknown. The last part of this dissertation is focused on a preliminary evaluation of the 
effect of EDL-291 on human glioma cell apoptosis machinery.  
 
Capase 3/7 activation is one of the biochemical hallmarks of apoptosis. After 
EDL-291 treatment, activity of caspase-3/7 and the amount of cleaved PARP, a product 
of activated caspase-3, were increased in human glioma cell lines. The antiproliferative 
effect of EDL-291 was partially reversed by the caspase-3/7 inhibitor, which confirmed 
the involvement of effector caspase activation in the action of EDL-291. However, 
neither the inhibitor of caspase-8 (initiator caspase for extrinsic apoptosis pathway) nor 
the inhibitor of caspase-9 (initiator caspase for intrinsic pathway) reversed the apoptotic 
effect of EDL-291. Therefore, the initiator caspase could be caspase-4, the initiator 
caspase for the newly discovered endoplasmic reticulum (ER) stress-induced apoptosis 
pathway. 
 
Surprisingly, the antiproliferative effect of EDL-291 can be enhanced, rather than 
reversed, by mitochondrial permeability transition (MPT) inhibitor decylubiquinone 
(dUb). The caspase-3/7 activation after EDL-291 treatment also can be enhanced by dUb. 
dUb shares structure similarity to X-linked inhibitor of apoptosis protein (XIAP) inhibitor 
embelin; thus, it may also inhibit XIAP and de-inhibit caspases. Therefore, dUb could be 
a candidate companion drug of EDL-291 analogs in treating glioma, which provides a 
potential direction for building a mechanism-based combination chemotherapy strategy. 
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